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Zusammenfassung 
Hintergrund & Ziele: Magenkrebs ist die zweithäufigste Ursache aller 
Krebstodesfälle weltweit. Fortgeschrittene Stadien von Magenkrebs sind oft 
verbunden mit limitierter und geringfügiger chemotherapeutischer 
Behandlungsweise. Dieser Fakt hebt den Bedarf an neuen Fortschritten in der 
Behandlung von Magenkrebs hervor. Krebsstammzellen (CSCs) sind bekannt als 
einer der verantwortlichen Hauptkandidaten für Tumorrezidive, Metastasen und 
Resistenz gegen Krebstherapien in verschiedenen Arten von Magenkrebs. Studien 
haben gezeigt, dass Notch- und wnt-beta-catenin-Signalwege äußerst entscheidend 
für die CSC-Entwicklung sind. In dieser vorliegenden Studie haben wir uns auf die 
einhergehende Aktivierung von Notch- und wnt-beta-catenin-Signalwege in CD44+ 
Magenkrebs beschäftigt. Wir haben ausserdem eine effektive Inhibierung von Notch- 
und wnt-beta-catenin-Signalwegen in CD44+ gastrischen tumorauslösenden Zellen 
durch Verwendung des γ-secretase Inhibitors IX (GSI IX) gezeigt. 
 
Methoden: Um den Effekt von GSI IX auf tumorauslösende gastrische CD44+ Zellen 
zu bestimmen, wurde das Wachstum, die epitheliale Plastizität und die 
Tumorentwicklung  nach GSI IX Behandlung bestimmt. Hierzu wurden in vitro-
Analysen zur Proliferation, Wundheilung, Invasion, Adhäsion und Tumorsphere-
Bildung mit der gastrischen Tumorzelllinie MKN45 durchgeführt, um das Migrations-, 
Invasions-, Adhäsions- und Tumorpotenzial zu untersuchen.Mittels Western Blot 
wurden Notch- und Wnt-beta-catenin auf auf die Aktivierung der 
Signaltransduktionskette nach gamma-secretase Inhibitor IX (GSI IX) Behandlung 
getestet.Immunhistochemie, Immunfluoreszenz und durchflusszytometrische 
Analysen wurden genutzt um die CD44- und Hes1-Expression in humanem Gewebe, 
Zellen und Blut von Magenkrebs zu bestimmen. Für in vivo-Analysen wurden mittels 
Durchflusszytometrie isolierte CD44+ Zellen subkutan in Nacktmäuse (NMRI-nu/nu) 
injiziert und mit GSI IX, oder PBS als Kontrolle, behandelt. 
 
Ergebnisse: Die Behandlung mit GSI IX inhibiert effektiv das Zellwachstum, 
Migration, Invasion, Adhäsion und induziert Apoptose in CD44+ gastrischen 
tumorauslösenden Zellen. Außerdem wurde eine komplette Inhibierung der Notch- 
und beta-catenin-nachgeschalteten Signalzielen beobachtet. Magenkrebspatienten 
mit einer Expression von CD44 und Hes1 zeigten allumfassend eine geringere 
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Überlebensrate. CD44+ CSCs zeigten eine hohe Expression von Hes1 im Vergleich 
zu der CD44- Subpopulation. Interessanterweise ist unter allen Notch rezeptoren 
Notch1 enorm wichtig in der Vermittlung einer Interaktion zwischen Notch- und wnt-
beta-catenin-Signalkaskaden in CD44+ CSCs. Eine Runterregulation von sowohl 
CD44 als auch Notch1 durch siRNA inhibierte nachgeschaltete Ziele und bestätigte 
die vorgeschlagene Hypothese, dass CD44 einer Interaktion der Signale in 
gastrischen Tumorzellen vermittelt. Die GSI IX-Behandlung inhibiert wirksam die 
einhergehende Aktivierung von beiden (Notch und wnt-beta-catenin) Signalwegen in 
Magenkrebs durch spezifisches Abzielen auf CD44+ gastrischen CSCs. 
 
Schlussfolgerung: Somit unterstützt unsere Studie das Vorhandensein von bislang 
identifizierten CD44+ CSCs in humanen gastrischen Tumorzellen. Außerdem hebt 
unsere Studie die Aktivierung von Notch und beta-catenin in gastrischen 
tumorauslösenden CD44+ Zellen und dessen wirksame Inhibierung nach einer GSI 
IX-Behandlung hervor. Zudem zeigte die Expression von CD44 und Hes1 doppelt 
positive Zellen eine starke Korrelation mit der gesamten Überlebensrate der 
Patienten. Dafür könnte GSI IX eine mögliche wirksame alternative 
Behandlungsmöglichkeit für Magenkrebspatienten sein. 
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Summary 
 
Background & Aims: Gastric cancer is the second most common cause of cancer 
related death in the world.  Advanced stages of gastric cancer are often associated 
with limited and marginal chemotherapeutic regimes. This fact further emphasises on 
the need of new advances in gastric cancer treatement. Cancer stem cells (CSCs) 
known to be one of the main candidates responsible for tumor recurrence, metastasis 
and resistance to cancer therapy are identified and charecterised in different types of 
gastric cancers. Studies have indicated that Notch and wnt-beta-catenin pathways 
are crucial for CSC development. Here in this study we higlight on the concomitant 
activation of Notch and wnt-beta-catenin pathway in CD44+ gastric cancer. We also 
showed effective inhibition of Notch and wnt-beta-catenin pathway in CD44+ gastric 
tumor initiating cells using the γ-secretase inhibitor IX (GSI IX) 
 
Methods: We analysed the effect of GSI IX on growth, epithelial plasticity and 
tumorogenicity of gastric tumor intiating CD44+ cells. We have used gastric cancer 
cell line MKN45 in our experiments. For in vitro analysis proliferation,wound healing, 
invasion, adhesion and tumorsphere assays were performed to analyse the migration 
,invasive, adhesive and tumorogenic potential of CD44+ sorted gastric tumor initaiting 
cells after GSI IX treatment. Western blot analysis of downstream signaling targets of 
Notch and wnt-beta-catenin were tested after gamma-secretase inhibitor IX (GSI IX) 
treatment. Immunohistochemistry, immunofluorescence and flowcytometric analysis 
were used to determine CD44 and Hes1 expression in human GC tissues, cells and 
blood. For in vivo analysis sorted CD44+ cells were subcutaneously injected into the 
nude mice (NMRI-nu/nu) and were treated with vehicle or GSI IX. 
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Results: GSI IX treatment effectively inhibits cell growth, migration, invasion, 
adhesion and induced apoptosis in CD44+ gastric cancer tumor initiating cells. 
Moreover, complete inhbition of notch and beta catenin downstream signaling targets 
were observed. Gastric cancer patientswith expression of CD44 and Hes1 showed 
overall reduced survival. CD44+CSCs showed high expression of Hes1 as compared 
to the CD44-subpopulation. Interestingly, amongst all Notch receptors, Notch1 was 
found to be important in mediating a crosstalk between Notch and wnt-beta-catenin 
signaling cascades in CD44+CSCs. Silencing of both CD44 and Notch1 by siRNA 
inhibited downstream targets and reconfirmed the proposed hypothesis of CD44 
mediated signaling crosstalk in GC cells. GSI IX treatment effectively inhibits the 
concomitant activation of both (Notch and wnt-beta-catenin) pathways in gastric 
cancer via specific targeting of CD44+ gastric CSCs. 
 
Conclusion: Thus, our study supports the presence of previously indentified CD44+ 
CSC in human gastric cancer cells. Our study also highlights the activation of Notch 
and beta catenin in gastric tumor initiating CD44+ cells and its effective inhibiton after 
GSI IX treatment. Moreover expression of CD44 and Hes1double positive cells 
showed a strong correlation with overall patient survival. Therefore, GSI IX could be 
a possible effective, alternative, treatment option for gastric cancer patients.  
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Introduction 
 
1.1 Gastric Cancer 
Gastric carcinogenesis is a multi-step process which is governed by several factors. 
Gastric cancer is categorized into mainly two types: intestinal and diffuse. Intestinal 
type of gastric cancer is mainly based on environmental factors like lifestyle, 
helicobacter pylori infection etc whereas diffuse type is often related to genetic 
abnormalities (Figure 1).  Gastric cancer remains to be seventh most common cause 
of cancer related death worldwide mainly due to poor prognosis. Advances in 
molecular medicine are of urgent need not only to understand in detail the 
carcinogenic process involved in gastric cancer progression, but also to offer new 
potential approaches for diagnosis, treatment and better therapeutic intervention (1, 
2, 3). 
 
 
 
 
Figure 1: Gastric cancer classification. According to the Lauren classification gastric 
cancer is divided into two main types depending on the factors involved in gastric cancer 
development (Adapted from 1). 
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1.1.1 Incidence mortality and survival 
 
Gastric cancer is one of the most common types of cancer prevalant worldwide and 
the third leading cause of cancer related death all over the globe. Interestingly, the 
global incidence rate of gastric cancer has declined rapidly over the past few 
decades mainly due to the identification of some of the common risk factors 
associated with gastric cancer progression. All though, the response rate of gastric 
cancer to multi-agent therapy is 50% or greater but the median survival rate is still 
limited. The five year survival rate of gastric cancer is less than 10% in western 
countries in comparison to Japan (over 50%). Moreover, limited patients can undergo 
curative surgery (3). The lack of curative therapeutic options makes gastric cancer as 
one of the most lethal and deadly disease for the mankind. In the United States 
approximately 22,220 patients are diagnosed annually with gastric cancer. China and 
Japan are the leading countries across the globe with a high rate of gastric 
cancer.Despite an overall decrease in gastric cancer incidence worldwide over the 
past few decades but interesting aspects such as age, sex etc. has been observed to 
play an important role in gastric cancer incidence. In China an increase in gastric 
cancer incidence has been observed in older patients as compared to younger once, 
a more remarkable difference has been observed between female, male genders. 
Notably, that age of onset of gastric cancer in China is younger compared to the west 
(4, 5). 
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Figure 2: Worldwide incidence and mortality rate of gastric cancer patients depending 
on gender (Male vs. Female) (GLOBOCAN 2012)(Adapted from 6). 
Geographical variations and migration studies has revealed an immense effect on 
the incidence rate of gastric cancer. Eastern Asia, Eastern Europe and South 
America has relatively higher incidence rate as compared to North America and parts 
of Africa (Figure 2). Importantly, a difference in incidence rate and mortality has been 
observed from North to South; Northern areas have a higher mortality rate compared 
to south. Such North/South divide for gastric cancer incidence and mortality has been 
observed in countries like Japan, England and China. Therefore, this fact highlights 
that geographical areas are associated with the incidence and mortality of gastric 
cancer. The histology pattern of gastric cancer is also changing with an increase in 
incidence of diffuse type of gastric cancer as compared to the intestinal type (7, 8, 9). 
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According to the GLOBOCAN database organized by the World Health Organisation 
(WHO) the country-specific mortality rate for gastric cancer reports an annual 
percentage change in gastric cancer mortality from 3 to 4 percent for the major 
European countries. Leading countries from other continents such as republic of 
Korea, Japan, Australia, United States and South America have shown an annual 
percentage change of 4.3%, 3.5%, 3.7%,3.6% and 2.6% respectively in mortality rate 
of gastric cancer (7, 8). 
Despite the decline in the mortality rate of gastric cancer the absolute number of new 
cases every year is increasing mainly due to the aging of the world population. 
Furthermore due to unclear reasons the decrease in mortality rate has been replaced 
by an upward trend for gastric cancer onset in younger patients in recent years. 
Therefore, gastric cancer will continue to be one of the alarming causes of cancer 
related death worldwide even in the foreseeable future (4, 5, 9). 
1.1.2 Symptoms and diagnosis of gastric cancer 
 
The classical representation of patients with gastric cancer is often well perceived. 
The main symptoms involved in gastric cancer are abdominal pain, anorexia, weight 
loss, vomiting and signs of anaemia. Gastric cancer is also associated with 
haematemesis, dysphagia and abdominal swelling due to ascites (2, 10). Abdominal 
mass is often identified in gastric cancer due to the presence of primary tumor or liver 
metastasis. Usually the recognition of such evident symptoms is always identified at 
a later or advanced stage thus the likelihood of a successful curative resection is 
often obscure. The chances of curative options like chemo or radiotherapy are limited 
therefore; in the majority of cases the only mode of treatment available is palliative in 
nature. Unfortunatley identification of these symptoms at an early stage during the 
evolution of the disease could be subjected to early endoscopy and treatment.  
However, this doesnot appear to be feasible as patients with early stages of gastric 
cancer are either asymptomatic or dyspepsia (no report of upper abdominal pain). 
According to a statistical report out of 100 patients of gastric cancer in Japan only 
66% were asymptomatic, 34% showed primary symptoms, 21% complained of 
discomfort and only 4 reported to have loss of appetite (2, 10, 11). Therefore, gastric 
cancer being the second most lethal form of cancer after lung cancer in the world the 
main reason for this appalling diagnosis can be attributed to the limitation of detection 
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of gastric cancer at an early stage. Unfortunately, the disease is always detected at a 
later stage of the evolution and has already metastasized (2, 10, 11). 
1.1.3 Morphology of gastric cancer 
 
The full story of gastric cancer still remains incomplete and is in evolution (2). Gastric 
cancer often markedly demonstrates heterogeneity at both architectural and 
cytological level with several histological elements. Over the past few decades 
gastric cancer has been histologically classified based on Laurens classification. 
According to Lauren’s classification gastric cancer can be classified into two main 
types: intestinal type and diffuse type adenocarcinoma and also indeterminate type is 
often considered as uncommon variant.The 2010 WHO classification recognized four 
major histological patterns of gastric cancer which includes tubular, papillary, 
mucinous and poorly cohesive. Poorly cohesive gastric cancer also includes signet 
ring cell carcinoma and the uncommon variant (1, 2, 12). 
Tubular adenocarcinoma is the most common histological type of gastric cancer. It 
mainly forms polyploidy with irregularly fused or branching tubules of various sizes. 
Papillary adenocarcinoma is a common histological variant often seen in stages of 
early gastric cancer. It is mainly associated with liver metastasis with high lymph 
node involvement, specifically characterized by epithelial projections with a central 
fibrovascular core. 
Mucinous adenocarcinoma accounts for 10% of gastric cancer. Histologically this it 
is mainly characterized by mucinous pools which form almost 50% of the tumor 
volume with occasional signet ring cells floating in these pools. 
Signet ring cell carcinoma is composed of a mixture of signet ring cells and non-
signet ring cells.These tumor cells form irregular lace like glandular structures 
accompanied by desmoplasia in the gastric wall with an ulcerated surface. Signet cell 
carcinoma and other poorly cohesive carcinomas at antroplyoric regions specifically 
shows propensity to invade duodenum via various submucosal routes. Therefore, 
special attention needs to pay to these routes during surgical resection. However, 
pseudo signet ring cells donot show any invasive pattern (4, 8, 11). 
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In addition to the above mentioned division the WHO classification also includes 
other uncommon histological terms such as adenosquamous carcinoma, squamous 
carcinoma, hepatoid adenocarcinoma etc (12). 
1.1.4 Genetics of gastric cancer 
 
During gastric carcinogenesis accumulation of genetic and molecular abnormalities 
occurs which includes inactivation of oncogenes, overexpression of growth factors, 
inactivation of tumor suppressor genes, DNA repair genes etc (2, 9, 12, 16). 
Many genes involved in gastric carcinogenesis have been linked to cancers of 
specific organs, and three forms of genomic instability have been identified in the gut. 
Chronic inflammation is implicated in the pathogenesis of most GI cancers, but it is 
not clear whether this is quantitatively sufficient to cause cancer by itself (2, 8, 10, 
12). 
Several genes are involved in the carcinogenesis of gastric cancer linked to cancers 
of specific genes. Three different types of genomic instability associated with gastric 
cancer have been identified in the gut. Chronic inflammation is implicated to 
pathogenesis of gastric cancer (15, 16). Gastric cancer is epidemiologically linked to 
chronic H.pylori infection, which is also responsible for chronic inflammation. 
Involvement of K-RAS mutation, loss of p53, inactivations of epigenetic and 
Epidermal Growth Factor Receptors (EGFR) are evidently found to be involved in the 
development of gastric cancer. However, there has not been any conceptual model 
involved in the sequential development of this disease as proposed for other gastro 
intestinal cancer. Interestingly, germline mutations in the gene of E-cadherin (an 
intracellular adhesion protein) are found in unique and rare form of familial diffuse 
gastric cancer (15). CDH1 and HER2 expression are also associated with hereditary 
diffuse gastric cancer (12). 
Nearly 1-3 % of gastric cancer arise from inherited genetic susceptibility such as 
hereditary diffuse gastric carcinoma (HDGC), familial adenomatous polyposis etc.  
HDGC is an autosomal disorder with high penetrance. 30% of HDGC individuals 
shows germline mutations in tumour suppressor gene E-cadherin or CDH1(CDH1 is 
a classical member of the cadherin superfamily). In HDGC inactivation of the second 
allele of E-cadherin due to methylation, loss of heterozygosity or mutation triggers the 
development of gastric cancer. It is diffucult to diagnose HDGC at an early stage both 
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histologically and endoscopically mainly due to high penetrance of CDH1 mutation 
with the carrier of this gene which, confers for about 80% of the life time risk of 
gastric cancer. Importantly, according to the international gastric cancer consortium 
CDHI molecular testing is the recommended way for medical testing of gastric cancer 
(3, 10, 12). 
HER2 (Human Epidermal Growth Factor receptor 2) gene amplification hasbeen 
identified in gastric cancer. HER2 is a 185kDa transmembrane tyrosine kinase 
receptor protein that regulates signal transduction in cell proliferation, survival etc. 
HER2 is a protooncogene of the EGFR and is located on the chromosome region of 
17q21. Interestingly, HER2 overexpression is mainly observed in intestinal tye of 
gastric cancer or in cancers located at the proximal end of the stomach(2). Intestinal 
type of gastric cancer usually predominates in the patients with hereditary 
nonpolyposis colon cancer (HNPCC). HNPCC is due to disordered DNA repair 
caused due to mutations in the DNA mismatch repair genes like MSH2 ( Mut2 protein 
homolog 2, is a tumour suppressor gene located in chromosome 2) or MLH1(MutL 
homolog 1 is located in chromosome 3 and is usually associated with nonpolyposis 
colon cancer). Gastric cancer is a common colonic manifestation of HNPCC as, 
patients with HNPCC show 12 to 13 fold increase in incidence in gastric cancer as 
cmpared to the genral population. Other inherited diseases that are closely 
associated with increased incidence of gastric cancer are Li Fraumeni syndrome (this 
syndrome is mainly caused due to germline mutation in TP53) etc.Familial 
adenomatouspolyposis, an autosomal dominant condition which is associated with 
APC mutation which often progresses to an overly malignant phenotype. Several 
cases of gastric cancer are reported in patients with APC phenotype (1, 7, 12). 
Numerous chromosomal abberations have been reported in gastric cancer 
depending on the histological type. These aberrations are dependent on the overall 
survival and other clinicopathological parameters. Fusion proteins are common in 
malignancies. In gastric cancer a similar fusion protein involving the ROS1 gene 
(ROS1 gene encodes for transmembrane receptor tyrosine kinase). This fusion 
protein occurs as a result of genetic rearrangement and the occurence of such fusion 
proteins is quite less in case of gastric cancer. Occurance of microsatellite instability 
occurs in more than 50% of gastric cancer cases. Microsatellite instability results 
from impairment of DNA mismatch repair. Gastric cancer can be categorised 
depending on the status of microsatellite instability, gastric cancer patients with high 
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percentage of microsatellite instability has high overall survival compared to the 
stable or low microsatellite instability (1, 6, 12, 17). 
Helicobacter pylori infection is pandemic all over the globe and has been associated 
with diverse clinical outcome. H.pylori infection is known to be associated with gastric 
cancer. The overall clinical outcome of gastric cancer largely depends on the overall 
distribution and severity of the infection induced by H. Pylori.  
The human genome epidemiology systemetic review (HuGE) showed a close 
association between the severity of gastric cancer and inflammation related genes. 
For example the carriage of IL1RN*2 was associated with increased risk of gastric 
cancer whereas IL1B-31C was associated with reduced risk of gastric cancer. Mucin 
1 (muc1) is an oncoprotein and a member of the mucin family (The mucins are a 
large family of heavily glycosylated proteins). MUC1 has been found to be relevant to 
the carcinogenesis of gastric cancer. Investigations revealed aberrant expression of 
MUC1 in gastric cancer tissues. MUC1, which is expressed on the surface of gastric 
epithelial cells helps in interaction with H.pylori during gastric cancer progression(3, 
8, 12). 
1.1.5 Current treatment for gastric cancer 
 
Despite of major advances in understanding of gastric cancer biology the median 
survival of gastric cancer patients is less than 12 months, therefore development of 
personalised treatment strategies still remains the main challenge. First line 
chemotherapy is the standard treatment option for patients with advanced stages of 
gastric cancer with a good overall clinical outcome (4). In contrary, the overall 
performance outcome of combinational therapy in case of gastric cancer is muchless 
in comparisontosingleagent therapy. A meta-analysis in 2010 showed that 
combinational therapy showed a modest survival benefit of 1.5 months to that of 
single agent therapy. The standard chemotherapeutic regime for combinational 
therapy in gastric cancer patients usually involves older regimes like 5-Flurouracil/ 
anthracyclines in combinationwithPlatin, Irinotecanor Fluoropyrimidines like 
Capecitabine, S-1. 5-FU still remains the main backbone of combinational treatment 
in advanced gastric cancer. In Japan other than 5-FU S-1 is a widely accepted 
treatment option for patients with advanced gastric cancer for both single or 
combinational treatment (2,3,10). Overall patientsreceiving S-1 treatmentexperienced  
less side effects than 5FU treatment like grades of ¾ neutropenia was 32.3% for S-1 
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to that of 5FU with 63.3%, complicated neutropenia 5.0% versus 14.4% and somatits 
1.3% versus 13.6%. Alternative treatment options as a replacementofCisplatinareof 
immense interest in gastric cancer cure at present. This is mainly because Cisplatin 
free regimes represent a more convenient therapeutic option and reduces the 
chances of hyperhydration or renal toxicity associated with cisplatin treatment. The 
use of oxaliplatin as an alternative option to Cisplatin is controversial. Al-Betran 
etal.,2008(14) conducted a study with 5-flurouracil (5FU) or leucovorin either in 
combination with oxaliplatin or cisplatin. This trial showed better tolerability of 
oxaliplatin in comparison to cisplatin. Whereas, in landmark REAL-2 trial revealed 
that oxaliplatin was not a superior option for cisplatin with epirubicin and either 5-FU 
or capecitabine treatment, as oxaliplatin treatment was found to be more toxic in 
comparison to these two standard chemotherapeutic agents. Irinotecan 5FU 
combinational treatment allthough, didnot show any overall beneficial time to 
progression outcome but the drug combination was well tolerated in patients with 
advanced gastric cancer (2, 3, 10, 17, 18). 
The main aim of second or later lines of therapies is to improve the overall clinical 
outcome with little or no toxicity. In a Korean phase III trial the beneficial outcome of 
second or third line chemotherapies in advanced gastric cancer was confirmed. In 
this trial the patients were treated in a 2:1 ratio with chemotherapy (docetaxel or 
irinotecan) or BSC. The overall median survival improved significantly in patients 
withchemotherpy in comparisonto BSC. The efficacy of bothDocetaxelandIrinotecan 
was comparable (1, 2). Targeted therapies are often an effective beneficial option for 
cancer treatment. Allthough, as mentioned before HER2 expression is a 
characteristic signature of gastric cancer but currently the prognostic value of HER2 
in advanced gastric cancer is controversial. Trastuzumab the standard chemotherapy 
for breast cancer is known to be an effective drug against HER2 as it interferes with 
HER2 expression. In a prospective randomised phase III trial showed Trastuzumab 
in combinatin with other chemotherapy in treatmentofgastriccancer.Trastuzumab in 
combination with cisplatin or S-1 hasshowninterestingoutcome. Therefore, the status 
of HER2 targeted therapy using Trastuzumab as a treatment option for advanced 
gastric cancer needs further investigations (17, 18). Lapatinib a tyrosinekinase 
inhibitor that blockes irreversibly to HER2 is an apporved second line treatment 
option for breast cancer. Randomised trials with Lapatinib in combinaion with 
Oxaliplatin etc didnot showanyadvantage in overall survival in gastric cancer 
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patients.For targeted therapy inhibition of Epidermal growth factor receptor 1 
(EGFR1) was an alternative approach as 50% of gastric cancer tissues showed an 
overexpression of EGFR1.  Clinical trials with Panitumumab (a human monoclonal 
antibody targeted against EGFR1) showedsignificantlyworseoverallsurvival in gastric 
cancer patients as a result the study needed to be terminated. Moreover, predictive 
biomarkers which could contribute to the efficacy of panitumumab could not be 
identified in gastric cancer (19). Anti angiogenic compounds like Paclitaxel, 
Ramucirumab showed significantly improved overall survival in gastric cancer 
patients. These data definately supports further development of anti-angiogenic 
agents in gastric cancer treatment (1, 2, 7, 16, 17, 18, 19). 
1.2 Notch pathway 
Notch signaling has been studied for centuries but recent development in genome 
wide or proteome wide investigations especially in model organisms has given a new 
surge and provided deeper insights into the Notch pathway. The basic 
characterisation of Notch signaling started with the discovery of Notch gene in 
Drosophilla melanogaster. Both vertebrate and invertebrate studies show that 
characterization ofNotchpathwayispleiotropic as it plays a fundamental role in cell 
fate determination and in all aspects of animal development. Importantly, Notch 
pathway has also been found to be involved in the development and progression of 
various cancers like pancreatic cancer etc (19, 20). 
1.2.1 Notch signaling overview 
Notch signaling is a critical pathway in metazoans that regulates important cellular 
activities like cell proliferation, differentiation and cell death. Notch is a cell surface 
receptor that sends short range signals via interactions with transmembrane ligands 
such as Delta commonly known as delta-like in human and serate comonly termed 
as Jagged in human present in neighbouring cells.This ligand binding leads to the 
cleavage and release of Notch intracellular domain (NICD). Translocation of NICD to 
the nucleus leads to the regulation of transcriptional complexes containing the DNA 
binding protein CSL (CBF1\RBPjK\Su(H)\Lag1), CSL is a DNA binding adaptor. CSL 
interacts with many proteins to form a repressor complex to preserve the closed 
chromatin confromation or activating complexes containng NICD. Followed by the 
synthesis, the Notch receptors are cleaved at site (S1) by protein convertases during 
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exocytosis. This in turn helps in the regulation of trafficking and signaling activity of 
Notch. While the passage through the Golgi different notch receptors get 
glycosylated by glycosyltransferses such as fringe. This in turn now determines the 
fate of response to various subfamilies of ligands. This along with other post 
translational modifications tune up the Notch activity in a context specific manner. 
Followed by ligand binding the activation of signal transduction occurs on 
endocytosis of ligand receptor complexes. Leading to the unfolding of the 
justamembrane negative control region also known as NRR (NRR is specific to Notch 
proteins). Unfolding of NRR results in the access of ADAM10 (a protease also known 
as KUZ). KUZ removes the NICD by cleavage at a specific site 2 or S2. Y-secretase 
(y secretase is a multi subunit protease complex that cleaves single pass 
transmembrane proteins within the transmembrane complex) then cleaves the 
transmembrane domain within Notch at site 3 (S3) resulting in the release of various 
forms of NICD. Interestingly, this productive interaction between the notch receptors 
and the ligands occur only when present in neighbouring cells i.e trans whereas 
when these receptors,ligands are present on the same cell i.e cis the interaction is 
inhibited. In canonical Notch signaling or also known as CSL mediated signaling 
NICD translocates to the nucleus and recruits adaptor proteins like Mastermind like 
(MAML). MAML inturn recruits histone acetyl transferase HAT p300. This activation 
leads to the transcription of Notch target genes such as the hairy and enhancer of 
split (HES) and Hes-related (HESR\HEY) family of basichelix-loop helix (bHLH).Thus 
everycleavednotch subunit reasembles into a single molecule which determines the 
NICD content present in the nucleus. During this transcriptional activation NICD is 
phosphorylated at its PEST domain by kinases like cyclin dependent kinase 8 
(CDK8) followed by proteosome degradation by E3 ubiquitin ligases like Sel10 (also 
known as Fbw7) (Figure 3). This limits the half-life of Notch canonical signaling and 
resets the cell for next pulse of signaling (20, 21, 22, 23). 
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Figure 3: Schematic representation of Notch signaling. Notch ligand and receptors are 
expressed on cell surface. On interaction or binding of the Notch ligand to its receptor on an 
adjacent cell leads to a series of proteolytic cleavages referred as S1 and S2 cleavage by 
gamma secretase enzyme. This results in the release of Notch intracellular domain (NICD) 
that subsequently translocates to the nucleus. On nuclear translocation of NICD, Notch 
signaling is activated NICD binds to CBF1 followed by recruitment of nuclear protein MAML, 
MAML recruits histone acetyl transfease  protein P300 , this results in the transcriptional 
activation of various Notch target genes  belonging to HES and HEY families (Adapted from 
28). 
 
Several studies have also revealed the existence of non-canonical Notch signaling 
pathway. Other signaling pathways can also be activated by cleaved NICD but 
independent of CSL. Interestingly, other signaling pathways like JAK/STAT, RTK, 
MAPK, FGF, Wnt etc can activate the non-canonical Notch signaling via activation of 
common Notch downstreams targets like Hes family oftranscriptionfactors etc. It is 
evident from some studies that such interactions of activation of non-canoncal Notch 
signaling pathway play role in both development and disease (20,21, 22, 23, 24). 
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1.2.2 Notch in development and disease 
 
Notch signaling pathway is one of the basic signaling pathways involved in 
development for both cell types and organogenesis. The role of Notch signaling 
pathway in drosophila was first studied due to the recognition of a dominant Notch 
winged phenotype in drosophilas. The importance of Notch signaling in human 
development and disease was first reported when mutations in Notch1 was identified 
to be associated with occurance of T-cell acute lymphoblastic leukeamia (T-ALL). 
Since then development of other developmental disoders associated with Notch 
signaling has been identified and different animal models has been developed to 
understand how different components of Notch signaling contributes to the 
development of various organs associated with these diseases (22, 25, 26, 31, 33). 
Notch3 mutations resulting from the loss or gain of cysteine residues in the epidermal 
growth factor like repeats was found to cause CADASIL (a disorder characterised by 
stroke and dementia).Pathological studies has shown accumulation of Notch 3 in 
braintissuesofthesepatients. Unfortunatley, the precise mechanism for this disorder is 
not known (22, 25, 27). 
Alagille syndrome is a multi system, genetic disorder that mainly effects the liver, 
heart and kidney. JAG1 mutations were identified in this disease which shows the 
pleiotropic function of Notch signaling in mammals.  
The ALGS liver disease requires most consistent medical treatment and is 
associated with various liver phenotypes. JAG1 or Notch2 mutations were found in 
the liver phenotypes seen in ALGS resulting in lethality/paucity in bile duct formation. 
This is mainly because Notch signaling plays an important role in bile duct formation, 
therefore mutations in Notch components leads to lethality in bile duct formation 
resulting in ALGS phenotype. ALGS phenotype also causes other anomalies like 
renal, vascular, cardiac etc (22, 25, 26, 27). 
Medulloblastoma is also known as malignant brain tumour in childhood. Several 
groups have reported the potential role of Notch signaling in medulloblastoma; 
studies showed the increased mRNA expression of Notch2 and its target gene Hes1. 
This coexpression was found to be associated with overall poor patient survival. 
Thus, Notch signaling can be a therapeutic target in treating medulloblastoma (22). 
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The role of Notch in differentiation, morphogenesis and development of central 
nervous system has been recently identified. Studies show that inactivation of Notch 
signaling elements leads to altered neurogenesis. In case of CNS altered 
neurogenesis mainly occurs due to low expression of notch downstreams like 
Hes1and Hes5 this results in the inability to generate NICD (22, 25). Notch signaling 
is also known to play a pivotal role in endocrine development i.e pancreas, gut and 
bone. Specific Notch pathway downstream elements are expressed during pancreas 
development. Thus,suggesting the role of Notch signaling in pancreatic development. 
Loss of function of a series of Notch target genes like Delta1, and Hes1 results in the 
accelerated or upregulated differentiation of pancreatic endocrine cells.  Notch target 
genes have been found to be involved in the early intestinal cell fate decision. 
Different notch target elements are expressed in murine crypts specifically Hes1 is 
expressed in crypts. Math1 mutant mice (a direct target gene of Hes1) died 
neonatally. Thus it shows that Hes1 and Math1 genes are important in determining or 
distorting the fate of differentiating cells (22, 25, 27). 
Intestinal epithelial cells shows an overexpression of NICD. Microscopic examination 
of the early developmental stages of the intestine revealed that NICD expression 
effects the overall architecture of the villi and also decides the fate of differentiated 
secretory cell lineage. Importantly, transcriptional analysis showed a direct 
connection between NICD overexpression and elevated levels of Hes1 transcription 
in the intestinal epithelium of the Hes1 transgenic mice. Genetic data thus, clearly 
shows that Notch mediated Hes1 expression determines the binary fate of adsorptive 
and secretory cells. Hes1 deficient mice didnot show any change in the proliferation 
of the intestinal precursor pool (22, 25, 26, 28). 
Osteoclastogenesis is a process of development of osteoclasts (osteoclast is a bone 
cell type that breaks down bone tissue). Osteoblastogenesis is a process of 
development of osteoblats (osteoblasts are cells with single nuclei that synthesize 
bones).  Evidences show that Notch pathway regulates both osteoclastogenesis and 
osteoblastogenes is during bone development. Notch activation downregulates the 
expression of c-Fms (c-Fms is a receptor for macrophage colony stimulation factor) 
in osteoclast precursor cells and also reduces the expression of osteoprotegerin ,also 
known as osteoclastogenesis inhibitory factor (OCIF) in stromal cells.  This results in 
the downregulation of osteoclastogenesis. Moreover, continuous NICD expression 
leads to the inhibition of osteoblast differentiation in osteoblast precursors. 
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Concomitant activation of Delta1 and Jagged1 has also been observed invivo during 
bone regeneration. All these observations together suggests a potential role of Notch 
pathways during bone regeneration and also in osteoporosis (22, 23, 25, 26). 
1.2.3 Notch signaling in cancer 
 
After the discovery of involvement of Notch signaling in T-ALL, the role of Notch 
signaling has also been implicated in various solid tumours like meduloblastoma, 
breast cancer, melanoma, non-small cell lung carcinoma etc. The oncogenic 
potential of Notch was first observed in Mouse Mammary Tumour virus (MMTV) 
driven breast cancer. Characterisation of MMTV driven breast cancer led to the 
observation of truncated levels of Notch 4. Importantly, in human breast cancer 
overexpression of Notch or Jag1 was observed and this overexpression directly 
correlated with poor prognostic outcome. Moreover, few activating mutations of notch 
has also been observed in the solid tumours of Non small cell lung carcinoma 
(NSCLC). Recent studies have also revealed Notch1 mutations in Chronic 
lymphocytic lymphoma (CLL). All though Notch1 mutations were not observed to be 
pathognomonic in development of CLL but led to poor patient survival. Therefore, 
targeting notch signaling could be of therapeutic interest in this distinct clinical 
subtype. (23, 29, 31, 32, 33, 36) 
In skin Notch activation induces differentiation and cell cycle arrest. Loss of function 
of  Notch1 resulted in basal cell carcinoma that appeared specifically in older mice. 
Thus Notch acts as a tumour suppressor in skin but the probable mechanistic 
approach still needs to be determined. Hepatocellular carcinoma (HCC) is one of the 
most devastating cancers worldwide. HCC mice model showed elevated levels of 
Notch pathway thus, activation of Notch is associated with HCC progression. Lobry 
et al., 2011 (29) showed that Notch loss of function or compound deletion of Notch1 
and Notch2 resulted in a myeloproliferative syndrome. This syndrome showed 
common features with chronic myelomonocytic leukemia (CMML). Stransky et 
al.,2011 (27)  and Agrawal et al.,2011(33) identified 28 different Notch1 mutations in 
17.5 % of head and neck squamous cell carcinoma (HNSCC) and also Notch2, 
Notch3 mutations in 11% of the patients.  Mainly loss of function mutation of the 
notch receptors was observed in HNSCC patients. In contrast to the oncogenic 
potential of Notch B cell malignancies reported that Notch suppressed growth and 
induced apoptosis in these cells. Thus providing additional information that Notch 
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could also act as a tumour suppressor in hematopoietic cells. In neuroblastoma 
similar tumour suppressor function of Notch was observed. Thus, these studies 
together suggest that Notch can also act as a tumour suppressor in some dieased 
models (23, 29, 31, 32). 
1.2.4 Notch signaling in gastric cancer 
 
In normal gastric mucosa Notch signaling is involved in the process of differentiation 
of the gastric epithelium into foveolar glands. Studies have shown expression of 
Notch1, Notch3, Jagged1, Jagged2 and Hes1 in the isthmus region of the normal 
mucosa where usually putative gastric cancer stem cells are found. Interestingly, 
Notch signaling is involved not only in the differentiation of normal gastric mucosa but 
also it is found to be involved in the differentiation of gastric cancer cells. Human 
gastric cancer tissues have shown expression of Notch receptors like Notch1, 
Notch2, Notch3 and also of ligands like Jagged 1 etc. Expression of Notch1 for 
instance is observed in both the premalignant and cancer tissues, specially in well 
differentiated intestinal gastric cancer. Piazzi et el.,2011 (30) showed that activated 
Notch1 has the potential to form solid tumours in human gastric cancer xenografts. 
This group also showed that increased expression of Delta-like 1, (DDL1, a ligand of 
Notch1) was associated with the increased activation of Notch1 and increased 
expression of NICD domain, Hes1 in gastric cancer cells. Importantly, in gastric 
cancer patients a strong correlation between DDL1 and Hes1 expression was 
observed. This correlation was found to be associated with overall patient survival. 
Patients with high expression levels of Notch3 and Jagged 2 show better clinical 
outcome to treatment as compared with patients with low level of expression. 
Therefore, Notch receptors and ligands could be a potential therapeutic targets for 
gastric cancer treatment. Studies also revealed that specially increased expression of 
Jagged 1 was clearly associated with aggressiveness of the cancer and resulted in 
overall poor patients survival. Thus, Jagged1 can act as an effective prognostic 
marker for gastric cancer. Inspite of knowing the contribution of Notch signaling 
receptors and ligands in gastric cancer progression, the exact mechanistic approach 
of Notch signaling cascade in gastric cancer still remains unknown. Some studies 
show that Notch1 activation in gastric cancer progression could be partially attributed 
to cycloxygenase2 (COX2). On treatment of gastric cancer cells with COX2 inhibitor 
showed impairment of migration, invasion and colony formation. Therefore, these 
studies clearly show that Notch signaling is involved in the pathogenesis of gastric 
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cancer but the level of expression of Notch ligands, receptors is cell type or 
circumstance specific. On a whole a better understanding of Notch mediated 
malignant transformation in gastric cancer could be useful in developing novel anti-
cancer strategies for gastric cancer treatment (28, 31, 32 ,34). 
1.2.5 Notch inhibition strategies 
 
Inhibition of Notch signaling specially in cancer is complicated due to the fact that 
pathway members donot have enzymatic activity themselves and mostly it is easier 
to develop small molecule enzyme inhibitors. In recent times inhibition of Notch 
signaling can be achieved by several different options as follows (Figure 4) (17): 
1) Small molecule inhibitors 
Canonical signaling of Notch pathway requires two series of enzymatic cleavage of 
activation first by alpha secretase complex and then by gamma secretase complex. 
This enzymatic activity can be inhibited by using small molecule inhibitors, Gamma 
secretase inhibitors (GSIs) represent the pioneering class of Notch inhibitors. GSIs 
were primarily developed for Alzheimer‘s disease but were later adapted for cancer 
therapy.  Importantly, GSIs have other targets than Notch receptors and ligands like 
CD44, E-cadherin, N-cadherin, Nectin 1 alpha etc (35, 36). 
 
2) Other potential approaches to small molecule inhibitors 
As an alternative to GSIs Alpha secretase inhibitors also known as ASIs has been 
developed. There function is not only attributed to the inhibition of notch signaling but 
ASIs are also knwon to be involved in impairment of ADAM (A Disintegrin And 
Metalloprotease). ASIs are known to be superior to GSIs:ASI does notneedtoenter 
the cell to act unlike GSI. ASI as a potential Notch inhibitor in cancer is still 
undertesting. 
It is possible to develop different small molecule inhibitors for Notch which can act in 
different fashions, as inhibiton of enzymatic activity is one of the most feasible way to 
achieve blockage of a specific protein or pathway. Recent studies show that there 
are likely to be other points of Notch pathway amendable to blockage. This 
alternative approach relies on the fact that gamma secretase cleavage of Notch is 
dependent not on the cell membrane but also in the acidic endosomes.  The Na+/H+ 
antiporter Monensin emerged as a potential acidification inhibitor for Notch.  The 
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supremacy of such inhibitors in comparison to GSIs in terms of specficity and 
effectivity still remains to be determined.  
 
A number of protein protein interactions involved in the Notch pathway like Notch-
Notch ligand etc could be potential targets to achieve inhibition of Notch pathway. 
Such a small molecule inhibitor involved in blocking of protein protein interaction is 
nutlin (nutlin interferes with p53\MDM2 interaction) (12, 21, 36). 
 
3) Antibody inhibitors 
 
Antibody inhibitors are a prominent means to interfere or block protein-protein 
interaction. One advantage of antibody inhibitors is their specificty to target each 
Notch family members or ligands involved in Notch activity. For some cancers local 
delivery is sufficinet as a curative option but for metastatic malignancies it is essential 
to have a systematic distribution. Therefore, antibody inhibitors of Notch are an 
effective approach for haematological malignancies or angiogenic uses as it requires 
effective distribution of the drug. 
Inhibition of Notch signaling via blockage of Delta like 4 ligand leads effective anti-
angiogenic strategies. Therefore blocking of Delta like 4 ligand with specific 
antibodies led to the impairment of tumour angiogenesis resulting in dysfunctional 
vasculature and tumour regression. Studies show that development of specific 
antibodies to different Notch family members can be beneficial in inhibiting cancer 
growth. For instance antibodies to Notch 3 that can block the Notch signaling 
cascade by blocking the target site for alpha secretase binding. This is achieved 
either by exposing the target site or by reinforcing its blockage. Usage of such Notch 
specific antibodies may be beneficial as a new modality to treat cancer with 
increased effectiveness and less toxicity (36, 37). 
 
4)Novel methods for Notch inhibition 
 
Notch inhibition can be achieved by the above mentioned strategies but recently the 
development of alternative new strategies are also emerging as an effective 
approach. These new approaches include usage of stapled peptide which blocks the 
interaction between Mastermind-like with NICD. This strategy of Notch inhibition was 
used by Verdine and Korsmeyer labs at Harvard by the development of a bcl2 
inhibitor. Recent reports have described the usage of a stapled peptide derived from 
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the alpha-helix of MAML protein termed as SAHM1. SAHM1 has the potential to 
block Notch canonical signaling which could be an effective therapeutic option for 
treating Notch dependent hematopoietic cancers such T-cell actue lymphoblastic 
leukemia etc (36). 
 
Geneticstrategiestoinhibit Notch signaling has also been developed, this usually 
involves delivery of a pseudo gene which encodes for a Notch inhibitory protein or 
peptide. Genetic inhibition startegies have limited application specially for 
haematological malignancies or specialised tumours. 
RNA interference is another strategy used recently but with more potential as a 
therapeutic startegy. Delivery of Notch inhibiting genes isthe main challenge 
therefore using RNA intereference which mainly involvesdeliveryof small 
oligonucleotides rather than the whole gene is comparitively less challenging. RNA 
interference usually involves usage of micro RNAs (miRNAs) or small-interfering 
RNAs (siRNA).  For example miR-326 is used to block Notch1 and Notch2 activity to 
inhibit Notch dependent cancer development. MicroRNAs offer the potential to 
suppress the activity of more than one target gene but the suppression is not as 
effective as siRNA mediated silencing of target genes for cancer cure. Therefore, 
whether usage of siRNA or miRNA could be a more effective approach to treat 
cancer still remains an open question (36, 37). 
 
 
                                                                                                                                                Introduction 
31 
 
Notch ligand
Notch receptor
B lock ing antibody
Alpha secretase ASI
NICD
NICD
Gamma secretase
GSI
HES, HEY
Stapled 
peptide
NUCLEUS
N
IC
DMAML
Gene delivery
R NA interference
 
Figure 4: Notch inhibition strategies. 
Different approaches of Notch inhibition in cancer therapy.      – showing blocking antibodies 
in order to inhibit Notch receptor ligand interaction. Alpha secretase and gamma secretase 
inhibitors to inhibit alpha and gamma secretase enyzmatic activity for release of  Notch 
intracellular domain and its translocation to the nucleus. Gene delivery ,RNA interference 
and usage of stapled peptides to suppress notch target genes like Hes, Hey etc. 
Abbreviations: NPR- negative regulatory region; NICD- Notch intracellular domain; ASI- 
alpha-secretase inhibitor; GSI- gamma-secretase inhibitor; MAML - Mastermind-like; HAT- 
Histone acetyl-transferase (Adapted from 36). 
1.3 CD44 in cancer stem cells 
A long standing goal has always been to understand which cancer or tumour cells 
need to be eliminated via treatment to achieve successful outcome. One framework 
that has received enough attention regarding this aspect is the “cancer stem cell 
hypothesis”. This hypothesis states that the cancer cells also have a sequential or 
hierarchial developmental structures which inculde some cells which can proliferate 
indefinately, these cells are charecterised as cancer stem cells. Therefore, targeting 
such cancer stem cell population could be of immense importance for cancer 
treatment. In order to target these cells, cell specific surface markers are required. 
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This concept led rise to cancer stem cell (CSCs) markers. Amongst several other 
markers CD44 is a widely used cell surface marker for cancer stem cells(38). 
 
1.3.1 Cancer stem cells (CSCs) 
 
A Tumour is not a mass of homogenous cells but also includes several different cell 
types like haematopeitic cells, enodthellial cells, stromal cells which can influence the 
function of the tumour as a whole. These heterogenous cells impact the tumour 
microenvironment like hypoxic environment etc which causes heterogenicity in 
tumour functions. Recently, studies are being conducted to reveal the underlying 
mechanism of tumour heterogencitiy and its impact on overall resistance to therapy, 
tumour progression or recurrence. According to the cancer stem cell theory within 
this heterogenous mass of tumour cells lies a subpopulation of self-renewing cancer 
cells known as the cancer stem cells (CSCs). Both experimental models and clinical 
studies show that CSCs are resistant to chemo or radio therapy (Figure 5). The 
above mentioned properties and transcriptional signatures are highly specific to 
CSCs and are also highly predictive in overall patient survival. Thus CSCs also have 
a huge clinical relevance.  Recentfindings in Leukeamiaand solid tumours indicate 
that the gene signatures specific to cancer and normal stem cells are highly 
prognostic for a wide spectrum of patients. In 1961 Till and McCulloch performed an 
in vivo clonal assay where he showed that one single clone of haemopoeitic cells 
were capable of undergoing multilineage differentiation but still retained the property 
of self renewal. Self-renewal property is often termed as "stemness" ofthecell. 
Stemness is an important characteristic property of stem cells. Stemness or the 
property of self-renewal is a key biological process in which one stem cell divides into 
one or two daughter cells which retain the capacity of self renewal. Therefore, 
ensuring that the stem cells population is maintained intact (38, 40, 41). 
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Figure 5: Stem cell in tumour. 
Heterogeneous mass of tumour tissue containing CSCs. Anti cancer drugs can target and kill 
the normal tumour cells but not the resistant cancer stem cells. These cancer stem cells 
causes relapse of tumour growth (Adapted from 42). 
 
Both CSCs and normal tissue stem cells both posses the property of self renewal but 
during carcinogenesis the self renewal property is typically deregulated. The basic 
defining feature of CSCs is they can be identified as a distinct population from the 
rest of the tumour possesing the potential of repopulation and self renew. CSCs on 
the basis of their self renewal property are also named as Tumour intiating cells (TIC) 
.TICs can be identified for their specific characteristics: Firstly, the potential of TICs to 
form xenograft tumours secondly, to self renew and finally, to produce daughter cells 
with the ability to proliferate. There are several evidences which show a strong 
linkage to stemness and therapy outcome as CSCs not only show resistance to 
cancer therapies but also invasion of cell death and dormancy as observed in colon 
cancer, breast cancer etc. Recently, it has been observed that in multiple myeloma 
CSCs are more resistant to a proteasome inhibitior used for treating the malignancy 
as comapred to the other bulk tumour cells. Emerging evidence also suggests a 
                                                                                                                                                Introduction 
34 
 
strong linkage to stemness and prognosis or therapy failure. This shows targeting 
CSC population can be of interest to eradicate the resistant self renewing population 
of CSCs present within the tumour and also to reduce the chances of relapse.In 
order to achieve specific targeting of CSCs identification of tumour specific CSC 
markers are of utmost importance. Recent studies have identified several cell surface 
marker for CSC like CD24, CD44, CD133 etc. Therefore, understanding the 
stemness property present within the tumour we are able to gain insight into the most 
important cell population present within the tumour capable of maintaining sequential 
rounds of tumour growth (38, 39, 40). 
 
1.3.2 CD44 
 
CD44 is a transmembrane glycoprotein that is known to have several functions in cell 
division, migration, adhesion, angiogenesis, presentaion of cytokines etc. CD44 
binds to its primary ligand Hyaluronic acid (HA). This binding leads to activation of 
cell signaling and also other important regulatory process within a cell. All of these 
process regulated by CD44 are important for normal cells but are also pivotal for 
cancer cells. CD44 being a cell adhesion molecule helps in cell-cell signal 
transduction. CD44 also regulates the signal transduction of common cell regulatory 
pathways like human epidermal growth factor (HER2) and MET receptor tyrosine 
kinase etc and leads to the activation of the downstream signaling cascade 
associated with important cell regulator processes. It has a molecular weight of 85-
200 kDa. Interestingly, binding of CD44 also results in stem cell homing. CSCs 
generate HA (the primary ligand of CD44 as mentioned above) in order to attract 
macrophages to the CSC niches. These CSCs in turn produce oncogenic growth 
factors which help to maintain the proliferative phase of the tumours. Moreover, 
interaction of CD44 with HA is also crucial for cellular invasion. In vitro studies of 
breast cancer cells have shown that metastasis can only be prohibited via 
preincubating the invasion chambers with anti CD44 oligos. This shows that CD44 
HA interaction is a pivotal process for invasion. However, how HA effects invasion 
still remains unclear.These evidences taken together shows that CD44 is expressed 
in CSCs and thus can be used as a marker to target CSCs. Experimental studies 
have also shown that targeting CD44 via usage of CD44 antibodies or CD44 soluble 
proteins have reduced the  maliganant activities in several neoplasms (44, 45, 49). 
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CD44 has 20 different isoforms generated due to alternative splicing. These different 
CD44 isoforms participate in various cell regulatory processes. The most commonly 
known isoforms of CD44 comprises of 12 isoforms. These isoforms are denoted as 
variants therefore, symbolised as "V" and the nomencleture is CD44v# (Figure 6). 
These variants can be isolated from normal cells and can also be obeserved in 
pathological cells. Out of these 20 different isoform CD44H is the most standard and 
simplest isoform. CD44H is well distributed since, it is a haematopoeitic isoform as it 
is found in whiteblood cell, natural killer cells etc it is denoted with H. Importantly, 
CD44 isoforms are also expressed in certain cancer metastatic stem cells. CD44v6, 
one splice variant of CD44 is known to be expressed and also known to be involved 
in breast and colorectal cancer. On a whole thus it can be concluded that CD44 
along with it ligands can modulate adhesiveness, motility etc and can also allow a 
tumour cell to proceed through all the steps of metastatic cascade (47, 49). 
 
 
Figure 6: CD44 splice variants. 
The basic outlook of CD44 splice variants (CD44 S and CD44 V). CD44S contains the basic 
domains (N-terminal domain, transmembrane domain and cytoplasmic domain).But CD44V 
has an additional longer stem containing variant exons (Adapted from 48). 
1.3.3 CD44 in gastric cancer 
Interest in gastric cancer stem cell has arisen in a broader context to the CSC 
hypothesis for tumour progression in cancer research. The new paradigm is 
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remarkable in the context that current anti-cancer therapies are more successful on 
the non CSC population of tumour cells compared to the CSCs. Thus identification 
and charecterisation of CSCs in cancer can be beneficial for therapeutic intervention. 
The in vitro studies by Takaishi and colleagues (50) as well as several other studies 
have identified CD44 as a cell surface marker for gastric CSCs. CD44+ population of 
gastric cancer cells showed property of self-renewal which is consistent with stem 
cell phenotype. Moreover, CD44+ cells showed resistance to both radio and chemo 
therapy thus reflecting them as an attractive target for gastric cancer treatment. 
Interestingly, among other CSC markers like CD133, CD24 etc majority of gastric 
cancer cells expressed more CD44 as compared to other markers being as high as 
95% (50, 51, 52) (Figure 7). 
 
 
Figure 7: CD44 in gastric cancer. 
A.Gastric cancer tumour mass containing gastric cancer stem cells like CD44, CD24.B. The 
detailed structure of CD44 containing the hyaluronan binding domain and variant domain 
(Adapted from 53). 
Taken together the studies suggest that CD44 fraction contain gastric CSCs. As 
CD44 is also present on non-tumorogenic gastric cancer cells therefore, identification 
of additional markers might also be helpful for narrowing down and identifying gastric 
CSCs. CD44 and its variants have been identified in gastric cancer and these 
variants have shown a correlation with poor prognosis specifically in patients 
identified with intestinal type gastric adenocarcinoma. Lau and his colleagues (51) 
A
. 
B 
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identified CD44 splice variant containing variable exons 8,9 and 10 were significantly 
elevated in gastric tumour compared to normal gastric tissue. Morover, they show 
that amongst the CD44 expressing gastric cancer cells, CD44 variant 8 to 10 is the 
major variant found in gastric CSCs.  CD448-10 is also found to play a functional role 
in gastric tumour initiation (45, 51, 54, 61). 
1.3.4 CD44 inhibition 
 
Understanding the role of CD44 in cancer progression led to the evolution of CD44 
as an attractivetargetin the field of cancer therapies. Several reports shows that 
inhibition of CD44 led to beneficial results in cancer treatment. Therefore, various 
approaches to inhibit CD44 in cancer progression was developed as an alternative 
strategy to treat cancer. 
Aptamers have been used as an alternative to antibody based therapies Lida J et al., 
2014 (56) developed an DNA aptamer Apt#7  which binds to CD44 exon  v10 and 
thus blocks the formation of CD44-EphA2 complex associated with  breast cancer 
migration. Apt#7 aptamer inhibited migration of breast cancer cells at comparatively 
low dosages like 5 to 10nM. Apt#7 aptamer not only inhbited migration but also 
invasion and inhibited various tyrosine kinase pathways associated with breast 
cancer development (56, 57). 
Studies showed a strong association in squamous cell carcinoma between CD44v6 
and tumour progression. There, a humanised monoclonal antibody against CD44v6 
named as Bivatuzumab was developed. Bivatuzumab was coupled with a cytotoxic 
drug mertansine in order to ensure effective treatment was used in phase I dose 
escalation studies in patients with head and neck squamoous cell carcinoma. This 
combinational treatment via inhibition of CD44 was found to be effective in 2 out 20 
patients undergoing the clinical trial. A similar study using radiolabelled humanised 
antibody against CD44v6 was developed for treating patients with early stages of 
breast cancer. Unfortunately, during clinical trials this drug needed to be terminated 
due to accumulation of the drug in non-tumorous areas and also failed to inhibit 
CD44v6 expression in breast cancer. 
A peptide against CD44v6 was developed with the potential to inhibit the association 
between CD44 MET and VEGFR2 (Vascular Endothelial Growth Factor Receptor 2) 
in endothelial cells. This v6 blocking peptide effectively inhibited angiogenesis and 
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metastasis in pancreatic cancer xenografts but this peptide has not been tested in 
clinical trials yet. The miRNA miR34a was recently identified as a regulator of CD44, 
miR34a expression resulted in degradation of CD44. The use of tmiR34a as a 
strategy to inhibit CD44 expression effectively inhibited tumour growth and 
metastasis in mice with prostrate cancer. Moreover, these miR34a treated prostrate 
cancer mice also showed overall increased survival (46). Natural compounds have 
also shown to be effective in inhibition of CD44.BXL0124 (a novel gemini vitamin 
Danalog) showed impairment of tumour growth and CD44 expression in human 
breast cancer both invivo and in vitro. It was observed that this natural compound 
effectively inhibited breast cancer growth via Vitamin D receptor and p53 dependent 
mechanisms (58, 59). 
1.3.5 Targeting pathways in CSCs 
 
Gaining insight about the mechanisms involved in the maintenance of self renewal 
potential is of importance for development of anti cancer drugs and targeting CSCs. 
Reports reveal that  wnt, Notch and Hedgehog are the threemain pathways that 
might be involved in the recurrance and maintenance of CSCs.  NF-κB, 
phosphatidylinositol 3-kinase (PI3K)/Akt, PTEN are also some of the common 
pathways which show aberrant activation in CSCs. It is believed that these pathways 
provides CSCs the potentail to initiate cancer and also promote recurrance after the 
surgical removal of the tumour (60). 
Hedgehog pathway is one of the key pathways known to be involved in the 
maintenance of CSCs. Canonical hedgehog signaling involves binding of three main 
hedgehog ligands Sonic (SHH), Indian (IHH), and Desert (DHH) to patched 
receptors. The ligands are differently expressed depending upon the cell type. This 
binding leads to the activation of transcriptional effectors of GLI family (50, 58, 60). 
Studies reveal the involvement of wnt signaling in the self renewal and maintenance 
of CSCs in several tissues like skin, intestine etc. Importantly, a subpopulation of 
tumour initiation cells associated with drug resistance showed activation of Wnt 
signaling. Inhibition of wnt signaling in these population led to the blockage of breast 
tumour growth in murine models.  wnt signaling is characterised by the canonical wnt 
pathway or the beta-catenin dependent pathway. Wnt signaling usually involves Wnt 
ligands, Frizzled receptors and formation of a complex composed of  APC, Axin1, 
Glycogen synthase kinase 3-β, and CK1 (casein kinase 1). Formation of this complex 
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leads to the stabilisation of beta-catenin which stimulates mediators controlling cell 
movement and behaviour (Figure 8). In vitro studies have showed that usage of beta-
catenin nuclear transfer inhibitor not only decreased significantly the colony formation 
of lung carcinoma cells but also importantly, downregulated pluripotent stem cell 
signaling pathway.  Studies have shown that usage of wnt inhibitors canpotentially 
eliminate the drug resistance associated with CSCs (58, 60, 63). 
 
 
 
Figure 8: Schematic representation of the overview of wnt signaling in maintenance of 
cancer stem cell.  
Wnt protein transduces extracellular message to intracellular signaling cascade by binding 
through frizzled receptors. β-catenin forms destruction complex (Axin1, 2/APC/CK1α and 
GSK-3β,). Phosphorylation of β-catenin within this complex leads to ubiquitin and 
proteosomal mediated degradation process. In the presence of wnt ligand wnt protein binds 
to frizzled receptors along with its LRP5/6 co-receptor complex leading to interruption of the 
destruction complex. The activated cytosolic accumulation of β-catenin, leads to 
translocation of beta-catenin to the nucleus. In normal stem cells, the Wnt pathway signaling 
causes activation of its target genes such as OCT4, Nanog and Sox-2 leading to 
maintenance of self-renewal property (Adapted from 59). 
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Interestingly, several reports show that amongst all of the above mentioned signaling 
cascades associated with CSC maintenance specifically Notch and wnt-beta-catenin 
pathways are found to be significantly active in gastric CSCs associated with gastric 
carcinogenesis, prognosis and chemotherapy resistance. Therefore targeting and 
impairment of these two pathways specifically could eradicate the targeted CSC 
population resulting in an overall effective clinical outcome (75, 83). 
1.4 Gamma-secretase inhibitor (GSI) 
Gamma-secretase is basically a large complex composed of two subunits: a catalytic 
subunit (consisting of presenilin-1 or presenilin-2) , accessory subunit (containing 
pen-2, Aph1, nicastrin) (63). The pivotal role of gamma secretase has been  
evaluated in the activation of Notch signaling, it hasbeen observed that point 
mutation in the cleavage site of Notch 1and also double knockout of presenilin-1or 2 
led to embryonic lethality in mice. Therefore, as gamma secretase inhibitors (GSIs) 
are able to block Notch receptor activation, several GSIs havebeen tested for its anti-
tumour effects (Table 1). 
Gamma-secretase is known to have several other substrates other than Notch 
ligands like ErbB4, Sydecan (an extracellular matrix) and most importantly CD44 
(35, 37, 41, 63). 
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Figure 9: Gamma-secretase inhibitor (DAPT) 
The chemical structure of Gamma-secretase inhibitor DAPT.DAPT is also known asN-[N-
(3,5-difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester, GSI IX or compound 3 (64). 
GSIs can be divided into three main classes : peptides, azepines and sulfonamides.  
Depending on the structure and function, GSIs can be categorised into two main 
categories 1) GSIs that mimic and competitively bind to the catalytic active site of 
Presilins present in gamma-secretase complex. For example DAPT, N-[N-(3,5-
difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester also commonly known as 
GSI IX or compound 3 (Figure 9).  2) DAPT potentiated the apoptotic effects in breast 
cancer cells. DAPT remains to be the start point of GSI mediated therapy as several 
other effective GSIs have been developed from DAPT (62). These GSIs bind to the 
interface of the gamma-secretase complex dimer. Forexample Tetarlin imidazole is a 
GSI that is in Phase I clinical trial of advanced breast cancer. 
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Table 1: GSIs undergoing clinical trial for various cancer treatments. 
Single agent or combinational use of GSIs currently undergoing Phase I\II clinical trials in 
advanced cancer (64). 
Both the GSIs were tested for Notch activity showed decrease tumour cell migration 
and also downregulation of common Notch HCC etc (64). GSI therapy is usually 
associated with nominal gastrointestinal side effects. Thus inhibition of Notch 
signaling via GSI IX to treat Notch active cancers could be of intense therapeutic 
interest in the foreseeable future (35, 64). 
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2. Aim of the study 
Gastric cancer is the third leading cause of cancer related death worldwide.Systemic 
treatment modalities have improved, but the median survival rate is still limited and 
the 5 year survival rate is less than 20%. Therefore, evolution of new treatment 
options are of urgent need in the field of gastric cancer. Cancer stem cells (CSC) 
have been identified in various cancers and are also known to be important in the 
occurence and metastasis of gastric cancer. CSCs are responsible for chemotherapy 
resistance and therefore a target of anti-tumour therapies. Therefore, in this present 
study we tried to specifically target the CSC population in gastric cancer using cell 
surface markers mainly CD44. Notch and wnt-beta-catenin pathways are also known 
to be the two main pathways involved in maintenance of CSC. Therefore, using GSI 
IX we mainly focused on concomitant inhibition of both Notch and wnt betacatenin 
pathways in the CD44+ population of gastric CSCs. Moreover, we also analysed the 
prognostic value of CD44 and Hes1 double positivity for gastric cancer.Thus, 
targeting of CD44 by GSI can evolve as an effective, potential therapeutic approach 
to treat patients with gastric cancer. Analysis of Hes1 and CD44 might help to 
monitor treatment outcome of gastric cancer as a new biomarker and also to predict 
prognosis of gastric cancer in this group of patients. 
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3. Material and Methods 
3.1 Material 
3.1.1 Expendable items 
 
Cover slip 
Freezing tube 
Microscope slides 
Transfer membrane 
Hyperfilm TM ECL 
Whatman 
Centrifuge tubes 
Dialysis tubing 
6 wells plate                                                  
12 wells plate                                                
96 wells plate  
Cell culture dishes 1000x15 mm 
Cell culture dishes 60x15 mm 
Micro tube 1,5 ml   
Filter Tips 0,1-10 ul 
Filter tips 20 ul 
Filter tips 200 ul 
Filter tips 1000 ul     
15 ml tube 
50 ml tube                                   
Menzel-Gläser, Braunschweig 
Sarstedt, Nürnberg 
Menzel-Gläser, Braunschweig 
PerkinElmer, Rodgau 
Amersham Bioscience, Braunschweig 
Omnilab, Elbingeröder 
Beckmann, Palo Alto 
Pierce, Rockford 
Sarstedt, Nürnberg 
Sarstedt, Nürnberg 
Sarstedt, Nürnberg 
Sarstedt, Nürnberg 
Greiner Bio-One, Frickenhausen 
Sarstedt, Nürnberg 
Sarstedt, Nürnberg 
Sarstedt, Nürnberg 
Sarstedt, Nürnberg 
Greiner, Solingen 
Sarstedt, Nürnberg 
Sarstedt, Nürnberg 
 
2.1.2 Equipments 
 
Agarose Gelelectrophoresis systems  
Centrifuge 5415 D 
Centrifuge Mikro 220 R cooled 
Megafuge 1.0 
Centrifuge “Rotina 38R” 
Centrifuge “L8-55M” 
Chaker vibramax 110                   
      Bio-RAD, München 
      Heraeus, Osterode 
      Heraeus, Osterode 
      Hettich, Tuttlingen 
      Beckman GmbH, Düsseldorf                                                                       
      GFL, Burgwedel 
      Heidolph, Kelheim 
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Clean Bench        
Easypet 4420                
Electrophoresis power supply 
Fluorescence microscope  
Gel chambers for proteins         
Heater     
Incubator                                                
Magnetic stirrers   
MicroPulser TM 
Microtiterplate luminometer  
Microwave   
Mini-Protein Electrophoresis System 
Mini Trans-Blot cell   
Mixer 5432     
Multipette® plus    
pH-meter 
Photometer 
Pipette 
Pipetman 
Power supplies    
Sonificator UP 200H                                        
Thermo cycler   
Thermomixer 5436       
ThermoStat plus  
Vortex-Genie           
Water baths                                                              
 
Hera Safe, Kendro, Osterode 
Sartorius, Göttingen 
Leica DM5000, Leica, Wetzlar 
Bio-RAD, München 
Bio-RAD, München 
Heraeus,Instruments GmbH, Osterode 
Heidolph, Kelheim 
Bio-RAD, München 
Tecan Deutschland GmbH, Crailsheim 
Bauknecht, Stuttgart 
Bio-RAD, München 
Bio-RAD, München  
Bio-RAD, München  
Eppendorf, Hamburg 
InoLab, Weilheim 
Eppendorf, Hamburg 
Eppendorf, Hamburg 
Hirschmann, Eberstadt 
Bio-RAD, München  
Gilson, Villiers le Bel 
Bio-RAD, München 
Hielscher, Stahnsdorf 
MWG-Biotech  AG, Ebersberg 
Eppendorf, Hamburg 
Eppendorf, Hamburg 
Janke & Kunkel, Staufen 
 
3.1.3 Softwares. 
 
Microsoft Excel 2007 (Microsoft Inc., Remond, Washington) 
Microsoft Word 2007 (Microsoft Inc., Remond, Washington)  
FlowJo Version 7.3 (Tree Star Inc., Ashland) 
BD Cell Quest ProTM (BD Biosciences, Mississauga) 
ImageJ 1.42 (Free Software Foundation, Inc., Boston) 
Adobe Photoshop 7.0 (Adobe Systems, San Jose) 
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MacVector Version 10.1 (MacVector Inc, Cambridge)  
3.1.4 Chemicals. 
 
Acetic acid       
Acetone 
Acrylamid-solution (30%) Mi 
37,5:1  
Annexin V conjugates 
Agar      
Agarose  
Ammoniumacetate 
Ammoniumsulphate 
Ampicillin 
Antigen unmasking solution 
Antifoam     
BactoTM peptone   
Benzamidine 
ß-Glycerophosphate 
ß-Mercaptoethanol    
Bromophenol blue 
Boric acid    
Bovine Serum Albumin 
Calcium chloride 
Caesium chloride 99% 
DAB substrate Kit 
DEPC 
dNTP 
EDTA 
EGTA 
Ethanol 
Ethanolamine    
Ethidiumbromide   
FCS 
Fibronectin 
Baker, Griesheim 
Merck, Darmstadt 
AppliChem, Darmstadt 
AppliChem, Darmstadt 
Bioline, Luckenwalde 
Bioline, Luckenwalde 
AppliChem, Darmstadt 
AppliChem, Darmstadt 
Vector, Eching 
Sigma-Aldrich, Schnelldorf 
Becton Dickinson, Heidelberg 
Sigma-Aldrich, Schnelldorf 
Roche, Mannheim 
AppliChem, Darmstadt 
AppliChem, Darmstadt 
AppliChem, Darmstadt 
Merck, Darmstadt 
Sigma-Aldrich, Schnelldorf 
AppliChem, Darmstadt 
AppliChem, Darmstadt 
Vector, Eching 
AppliChem, Darmstadt 
Fermentas,  St. Leon-Rot 
AppliChem, Darmstadt 
AppliChem, Darmstadt 
Meck, Darmstadt 
Sigma-Aldrich, Schnelldorf 
AppliChem, Darmstadt 
Biochrome, Berlin 
Calbiochem, Darmstadt 
GE Healthcare, Darmstadt 
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Ficoll-pague TM plus 
Formaldehyde solution min. 
37% free from acid   
Gelatine     
Glucose                                                                        
Glutamax                                                                      
Glycine   
Gamma secretase inhibitor 
(GSI) 
Guanidine thiocyanate                                                     
HEPS      
30% H2O2 
Hot start DNA Polymerase 
Hiperfect transfection reagent 
Hyaluronic acid 
Imidazole         
Isopropanol                                                                     
Kanamycinesulfate     
Lauroylsarcosine                                                       
Luminol min 97%, HPLC      
Magnesium chloride                                                         
Methanol    
Mounting Medium 
MTT assay WST-1 
Sodium 
Sodium chloride 
Noble Agar  
Nonfat dried milk powder 
Nonidet P40 
Normal Horse Serum 
p- Cumaric acid  
Penicillin-Streptomycin solution                                                                 
Phenol        
Polyethylenimine   
Merck, Darmstadt 
Sigma-Aldrich, Schnelldorf 
AppliChem, Darmstadt 
Invitrogen, Karlsruhe 
AppliChem, Darmstadt 
GE Healthcare, München 
Sigma-Aldrich, Schnelldorf 
Merk, Darmstadt 
Sigma-Aldrich, Schnelldorf 
AppliChem, Darmstadt 
Sigma-Aldrich, Schnelldorf 
Qiagen, Hilden 
Qiagen, Hilden 
Calbiochem, Darmstadt 
AppliChem, Darmstadt 
Merck, Darmstadt 
AppliChem, Darmstadt 
Sigma-Aldrich, Schnelldorf 
Sigma-Aldrich, Schnelldorf 
AppliChem, Darmstadt 
AppliChem, Darmstadt 
Vector, Eching 
Roche, Mannheim 
AppliChem, Darmstadt 
AppliChem, Darmstadt 
BD Difico, Heidelberg 
AppliChem, Darmstadt 
AppliChem, Darmstadt 
Vector, Eching 
Merck-Schuchard, Darmstadt 
Invitrogen, Karlsruhe 
AppliChem, Darmstadt
PfuTurbo DNA polymerase, Dresden  
Roth, Karlsruhe 
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Ponceau S solution                                                                     
Potassium acetate                 
Potassium chloride 
Potassium dihydrogen 
phosphate                                    
Prolong® gold antifade reagent                                      
Propidium iodide 
Proteinase K 
Restriction enzymes                                                                                                                                                   
SDS                                                                                                                                                                    
Sodium carbonate                                                            
Sodium chloride                                                                
Sodiumdihydrogenphosphate 
Sodium floride                                                                                                                           
Sodium pyrophosphate                                                    
Talon metal affinity resins                                                
TEMED                                                                             
Thymidine 99-100%    
Thermo Pool buffer          
Tris                                                                                    
Triton X 100                                                                      
Trypsin/EDTA solution   
Trypton 
Tunicamycin 
Tween-20                                                                          
Urea 
Vectastain Elite ABC-
Peroxidase Kits 
X-Gal for microbiology BC                                                                 
Xylenecyanol  
Sigma-Aldrich, Schnelldorf
AppliChem, Darmstadt 
AppliChem, Darmstadt 
AppliChem, Darmstadt 
Merck, Darmstadt 
Invitrogen, Karlsruhe 
Fluka, Steinheim    
AppliChem, Darmstadt 
NEB, Fermentas
AppliChem, Darmstadt 
AppliChem, Darmstadt     
AppliChem, Darmstadt  
AppliChem, Darmstadt      
AppliChem, Darmstadt                                                                                                                                                                                                                                                                                                                                                     
Sigma-Aldrich, Schnelldorf 
Becton Dickinson, Heidelberg 
AppliChem, Darmstadt 
Sigma-Aldrich, Schnelldorf 
Biolabs, Frankfurt 
AppliChem, Darmstadt 
AppliChem, Darmstadt 
Biochrom, Berlin 
AppliChem, Darmstadt 
Sigma-Aldrich, Schnelldorf 
AppliChem, Darmstadt 
AppliChem, Darmstadt  
Vector, Eching 
Peqlab, Erlangen 
AppliChem, Darmstadt  
AppliChem, Darmstadt  
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3.1.5 Buffers and solutions 
3.1.5.1 Buffers for the cell culture 
 
10X PBS 
Constituent Volume 
Nacl 137mM 
KCL 2,7mM 
Na2HPO4 100mM 
KH2PO4 2mM 
Table 2: Constituents of 10X PBS 
The pH was adjusted to 7,4. PBS was sterilised by autoclaving.  
 
Annexin-binding buffer pH 7,4 
Constituent Volume 
HEPS 10mM 
Nacl 140mM 
Cacl2 2,5mM 
Table 3: Constituents of Annexin-binding buffer 
 
Proteinase K buffer 
Constituent Volume 
Tris pH 8,5 100mM 
EDTA 5mM 
SDS 0,2% 
Nacl 200mM 
ddH2O 100ml 
Table 4: Constituents of Proteinase K buffer 
3.1.5.2 Buffers and solutions for protein extraction and analysis 
3.1.5.2.1 Protein extraction 
 
RIPA 
Constituent Volume 
Tris pH 8,0 50mM 
Nacl 80mM 
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NaF 50mM 
Na4P2O7 20mM 
EDTA 1mM 
EGTA 1mM 
NP-40 1% 
DOC 1% 
SDS 0,1% 
Table 5: Constituents of RIPA buffer 
 
NP40 
Constituent Volume 
Tris pH 7,5 50mM 
Nacl 150mM 
NaF 50mM 
Na4P2O7 20mM 
EDTA 1mM 
ß Glycerolphosphate 10mM 
Table 6: Constituents of NP40 
 
4XSB 
Constituent Volume 
Tris pH 6,8 0,25 M 
SDS 8% 
Glycerol  40% 
ß-Mercaptoethanol 10% 
Bromophenol blue 0,05% 
Table 7: Constituents of 4XSB 
Protease and phosphatase inhibitors (for 10 ml buffer) 
Name of the inhibitor Type Final concentration 
Vanadat Tyrosine-phosphatase 100µM 
Leupeptin Aspartic protease 0,5 ng/ml 
Leupeptin Serine-cystein protease 0,15mM 
Benzamidin Trypsin, thrombin, Plasmin 0,5% 
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Aprotonin Trypsin, chymotrypsin, 
kallikerin 
0,5mM 
PMSF Serine-protease 0,5mM 
Table 8: List of the used protease and phosphatase inhibitors 
3.1.5.2.2- Protein analysis 
 
Separating Gel 
% Acrylamide 7,5 % 10 % 12 % 14 % 15 % 
Acrylamide 2,5 ml 4,1 ml 3,4 ml 2,7 ml 2,45 ml 
Tris pH 8,0 2,5 ml 2,5 ml 2,5 ml 2,5 ml 2,5 ml 
H2O 4,85 ml 4,1 ml 3,4 ml 2,7 ml 2,45 ml 
10 % SDS 100 ul 100 ul 100 ul 100 ul 100 ul 
TEMED 15 ul 15 ul 15 ul 15 ul 15 ul 
10 % APS 105 ul 105 ul 105 ul 105 ul 105 ul 
Table 9: Constituents of the used separating gels 
Stacking gel 
Constituent 
 
Volume 
Acrylamide 1,13ml 
Tris 6,8 pH 1,75ml 
 ddH2O 3,2ml 
10% SDS 70ul 
TEMED 7µl 
10% APS  70µl 
Table 10: Constituents of the used stacking gel 
 
SDS running buffer (10x) 
Constituent Volume 
Tris pH 8,3 250mM 
SDS 1% 
Glycine 1,92M 
Table 11: Constituents of SDS running buffer (10X). 
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Western transfer buffer (10x) 
Constituent Volume 
Tris 250mM 
Glycine 1,92M 
Table 12: Constituents of western transfer buffer (10X). 
TNT western blot washing buffer (10x) 
Constituent Volume 
Nacl 1,5M 
Tris pH 7,5 100mM 
Tween-20 0,5% 
Table 13: Constituents of western blot washing buffer (10X). 
 
Blocking solution     
Milk powder, nonfat 5 % in TNT 
 
ECL solution 
Solution 1 
Constituent Concentration 
Luminol  250 mM  
p-cumaric acid  0,4 mM  
Tris pH 8,5  0,1 M 
Table 14: Constituents of ECL solution (solution 1) 
 
Solution 2 
 
 
 
 
Table 15: Constituents of ECL solution (solution 2) 
Constituent Concentration 
Tris pH 8.5 0.1M 
30% H2O2 0.061% 
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2.1.6.2 Solutions used for immunohistochemistry 
 
Antigen Unmasking Solution 
Antigen unmasking solution          1:100 diluted in dH2O  
 
Blocking Solution (in PBS) 
Constituent Volume 
Normal Horse serum 5% 
Triton X-100 0.3% 
Table 16: Constituents of blocking solution for immnuhistochemistry 
 
Acid Rinse Solution 
Constituent Volume 
Glacial Acetic acid 2% 
Table 17: Constituents of acid rinse solution for immnuhistochemistry 
 
Ethanol  
100%, 95%, 70%, 40% 
3.2 Methods 
3.2.1 Cell culture 
 
Human gastric cancer cell lines (2313287, KATO III, SNU1, NCI-N87 MKN 45) were 
obtained from Derek Zieker (Wiesbaden, Germany) and Kuang Hung Cheng 
(Kaohsiung, Taiwan). Human pancreatic cancer cell line KP3 was obtained from 
Nabeel Bardeesy (Boston, USA). MKN45 was cultured in RPMI 1640 + Glutamax 
(Invitrogen, Karlsruhe, Germany) supplemented with 20% FCS (Biochrom, Germany) 
and 100 U/ml penicillin/streptomycin (Invitrogen,Germany) at 37°C in 5 % CO2. KP3, 
2313287, SNU, NCI-N87 were cultured under same conditions, supplemented with 
10% FCS 100 U/ml penicillin/streptomycin (Invitrogen, Germany) at 37°C in 5 % CO2. 
KATO III cells were cultured in DMEM (Invitrogen, Karlsruhe, Germany) 
supplemented with 10% FCS and 100U/ml penicillin/streptomycin (Invitrogen, 
Germany) at 37°C in 5 % CO2. Cells were checked for authenticity every six months 
by growth curve analysis, morphology check by microscope. Cells were regularly 
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checked for mycoplasma contamination. Adherent cells (2313287, SNU1,NCI-
N87,KP3) were subcultured in every two days on reaching 70-80% confluency. For 
subculturing the adherent cells, the cells were trypsinised with 1 ml of trypsin at 37°C 
incubator for few minutes to collect the adherent cells and were transferred into new 
cell culture plates containing fresh medium. Suspension cells (KATO III, MKN45) 
were collected as a pellet by centrifugation (1000 rpm for 5 minutes), resuspended in 
fresh medium and transferred into new culture plates. Cells were cultured for a 
limited passage. Cells were frozen for long term storage, in order to freeze the cells 
both adherent and suspension cells were collected by centrifugation at 1000 rpm for 
5 minutes . The pellet was resuspended in freezing medium (1x106 cells/ml) (FuCS 
with 10% DMSO), DMSO was  used as a cryoprotective agent. The freezing medium 
was prepared fresh during each time of freezing. Frozen cell aliquots were stored at 
-80°C. 
3.2.2 Drug preparation and in vitro treatment 
 
3.2.2.1 Drug preparation 
 
Gamma secretase inhbitior IX , GSI IX (Calbiochem, EMD Chemicals) is provided as 
a 200mg light protective lyophillised powder from the company. GSI IX was prepared 
as 100mM stock in dimethylsulfoxide, DMSO (AppliChem, Darmstadt) and stored in 
light protective vials at -20°C.  
 
3.2.2.2 Drug treatment in vitro 
 
Human gastric cancer cell MKN45 were treated with dimethylsulfoxide, DMSO 
(AppliChem, Darmstadt) or GSI IX (Calbiochem, EMD Chemicals) in different 
concentrations (2.5µM, 5µM and 15µM) and were analyzed after  48hours and 
96hours . 
 
3.2.3 Apoptosis Assay 
 
In order to detect the induction of apoptosis in MKKN45 cells by GSI IX cells were 
subjected to apoptosis analysis using Annexin V\PI staining kit (Annexin V FITC 
Apoptosis Detection Kit I, BD Biosciences). For apoptosis cells were seeded in 6-well 
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tissue culture plates at a density of 1x10
5
cells per well and were incubated over night 
at 37
0
C. These cells were further treated with DMSO or GSI (2.5, 5 and 15µM) for 48 
and 96 hours. The medium was changed every two days. At 48 and 96 hours, the 
cells were harvested. The cells were washed with 1×PBS and trypsinised with 1ml 
trypsin for few minutes at 37°C incubator. The cells were collected after trypsinisation 
by centrifugation for 5 min at 1000 rpm. The cell pellet was resuspended with 1 ml 
1×PBS and centrifuged for another 5 minutes. The supernatant was discarded again, 
the cell pellet was suspended with 1ml 1x Binding Buffer (FITC Annexin V Apoptosis 
Detection Kit I, BD Biosciences) on ice. The untreated cells were divided into three 
tubes (Annexin V-control, PI-control and unlabeled control). 5μl Annexin V and 10μl 
PI (Annexin V FITC Apoptosis Detection Kit I, BD Biosciences) were added into the 
corresponding tubes. The samples were incubated for 15 minutes on ice and were 
further subjected to FACS analysis. The signal was detected using FACS calibur flow 
cytometer (BD, Heidelberg) and analyzed using FlowJo Version 7.6 software (Tree 
Star Inc., Ashland, USA). Characterized proportion of apoptotic cells in the untreated 
cell population compared to the total cell population of apoptotic cells was subtracted 
to obtain the respective proportion of the cells undergoing apoptosis, under each 
experimental condition. Living cells are thus Annexin V and PI negative. Early 
apoptotic cells are Annexin V positive and PI negative. Late apoptotic cells or dead 
cells are both Annexin V and PI positive. The quantitative measurement of the 
percentage of apoptotic cells is usually performed in the whole population following 
the manufacturer’s protocol (Annexin V FITC Apoptosis Detection Kit I, BD 
Biosciences) 
 
3.2.4 Cell proliferation assay 
 
In order to measure the effect of GSI on cell proliferation, CD44+ MKN45 cells were 
plated at a concentration of 1000 cells/ ml in a 96 well plate overnight. Cells were 
treated with DMSO, different concentrations of GSI (Merck KGaA) (2.5µM, 5µM 
and15μM) or 5-fluorouracil (5FU) (Sigma Aldrich, USA) (15µM) for 4 days. At each 
time point starting from 24 hours to 96 hours, 10 μL WST-1 reagents (Roche 
Diagnostics, Germany) was added to each well and incubated for 2 hours at 37°C 
light protected. The absorbance was detected at a wavelength of 492 nm with 
reference wavelength of 650 nm. Light microscopic pictures (10X magnification) were 
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taken for cells treated with DMSO or GSI on the final day (96 hours) of the 
experiment. The relative cell number was determined by plotting the optical density 
(OD) of cells under GSI treatment compared to the DMSO treated cells for each time 
points. 
 
3.2.5 Migration Assay 
 
Migration analysis was done in order to analyse the effect of GSI IX treatment on 
migration of cells. CD44+MKN45 cells were seeded in a 6-well plate and left to reach 
80% confluency. Initially, cells were starved for 24hours in media containing 2% FCS.  
Then the sorted cells were further incubated for 48hours in the starvation media 
containing either the control with DMSO, different concentrations of GSI (2.5µM, 5µM 
and15μM). Afterwards a scratch was done using a white tip for each treatment.  Then 
cells were washed with PBS and photographed using Leica DMI 6000 B microscope 
(Leica). Cells were incubated for an additional 24hours after which the photographs 
were taken for the wounded area. The migrating cells were calculated according to 
the following formula:  
 
                               Width of the wound at 0h - Width of the wound at 24h 
Migration Index =  ------------------------------------------------------------------------- x 100 
                                           Width of the wound at time 0h 
 
For each treatment, the difference in wound diameter between time 0hour and 
24hours was determined in relation to the 0hour reading. Since each wound has 
several measuring points, an average was determined for calculating the migration 
index. 
 
3.2.6 Invasion Assay 
 
In order to perform an invasion assay the invasion chambers (BD Biosciences, UK) 
were acclaimatized to room temperature and rehydrated serum-free medium for 2 
hours at 37° C incubator were CD44+MKN45 cells (2.5x105 cells / 2ml) were seeded 
in serum free media into each well of the 6-well BD BioCoat™ Matrigel™ Invasion 
Chamber (BD Biosciences).  The cells in the inserts were simultaneously treated with 
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GSI (2.5µM, 5µM and15μM) and the DMSO control. The inserts were placed into the 
BD Falcon TC Companion Plate containing 10% FCS and incubated for 48 hours in a 
humidified tissue culture incubator, at 37°C, 5% CO2 atmosphere. Then the invading 
cells were fixed with 100% methanol (AppliChem, Darmstadt) and stained with 1% 
toluidine blue (Sigma-Aldrich, St. Louis, USA) in 1% borax (Sigma-Aldrich, St. Louis, 
USA). Cells were then counted under the microscope (Leica DM 5000 B, Leica, 
Germany). The calculation of the invading cells was done according to the BD 
protocol where: 
                                % Invasion Test Cell 
Invasion Index =     --------------------------------  
                                % Invasion Control Cell 
3.2.7 Western blot 
3.2.7.1 Protein quantification 
 
The protein quantification was carried out according to manufacturer's instructions for 
Protein Assay kit (BioRad). 5µl of each protein sample was added as triplicates to a 
96 well plate. 20µl of reagent S was added to an Eppendorf containing 1ml of reagent 
A. 25µl of Reagent (A+S) was added to each well. 200µl of Reagent B was added to 
each well and the plate was incubated for 20 minutes light protected at room 
temperature. The absorbance (650nm) was measured with the Micro plate-Reader 
Multiskan Plus (Titertek-Berthold, Pforzheim). The mean value of the protein sample 
from the triplicate well was used for analysis. The amount of cell lysate in 1μl 
calculated as follows: 100 / ((x-0.0627) / 0,136). The net volume of the protein was 
standardized to 100µl containing 25µl of 4X loading dye.  
 
3.2.7.2 Sample preparation and Western blotting 
 
The cell were collected and transferred to 15ml test tubes and centrifuged for 5 min 
at 1000rpm. The supernatant was discarded, the cell pellet was resuspended with 
1ml ice cold 1×PBS and centrifuged again. The supernatant was discarded and the 
cell pellets were incubated in 200μl Western lysis buffer buffer supplemented by 
protease and phosphatase inhibitors for 30minutes on ice. The samples were 
sonificated on ice (15 seconds per sample). Thereafter, the suspensions were 
centrifuged for 25 minutes at 13000 rpm and 4°C. The samples were stored at -20° C 
until used. 
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CD44+MKN45 cells were cultured with DMSO or GSI (2.5µM, 5µM and 15µM). 
Harvested cells were lysed in lysis buffer containing 20mM Tris, 150mM NaCl, 1mM 
EDTA, 1mM EGTA, 1% Triton X-100 and protease and phosphatase inhibitor 
(Protease Inhibitor Cocktail Tablets, Roche). The concentration of extracted protein 
was determined using DC protein assay kit (Biorad) following manufacturer’s 
instruction as mentioned above. Samples were denatured in gel loading buffer by 
heating at 95°C for 5 minutes. For western blotting the cell lysates were loaded at a 
protein concentration of 30μg per well. Gel electrophoreses (12% acrylamide gels) 
was performed (Biorad). Initially the electrophoretic separation was conducted at 80V 
until the separating gel was reached, then the voltage was increased to 120V.  The 
PVDF membrane was briefly incubated in 100% methanol for activation followed by 
equilibration of the membrane in 1x transfer buffer for few minutes. The gel was then 
placed into the western blot cassette (the order of the western blot sandwich: 
sponge-filter paper- PDVF membrane- gel-sponge-filter paper). The cassette was 
placed into the western blot apparatus and run at 100V for 1 hour.  The membranes 
were blocked using 5% dried milk (AppliChem) for 30 minutes at room temperature. 
The membrane was subsequently washed thrice with 1X TNT, 10 minutes for each 
wash. Then the membrane was probed with primary antibodies overnight in 1X TNT 
at 40C. After overnight incubation of the primary antibody, the membrane was 
washed thrice with PBS (5 minutes each wash). After washing the secondary 
antibody was added in 1X TNT and incubated for 1 hour at room temperature. After 
another three washes with 1xTNT wash buffer the PVDF membrane were exposed to 
Amersham Hyperfilm ECL (GE Healthcare Limited Buckinghamshire), ECL-films. 
 
Target  Working dilution Source Manufacturer 
Anti-E-Cadherin 
Rabbit mAb  
1:1000 Rabbit Cell signaling 
Anti-N-cadherin 
rabbit monoclonal 
1:50000 Rabbit Cell signaling 
Monoclonal anti-
Actin (C-2) 
1:10000 Mouse Santa Cruz 
Biotechnology 
Anti-CD44 antibody   1:1000        Mouse Cell signaling 
Hes1 antibody 1: 500 Mouse Santa Cruz 
Biotechnology 
p-AKT    1:500 Rabbit Cell signaling 
Beta-catenin                                       1:1000 Rabbit Cell signaling 
P-Stat3(Tyr 705)                                 1:1000 Rabbit Cell signaling 
Rac1 1:500 Rabbit Cytoskeleton Inc., 
PARP 1:1000 Rabbit Cell signaling 
P21   1:500 Rabbit Cell signaling 
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MAPK (Erk 1/2)                                   1:500 Rabbit Cell signaling 
STAT3    1:500 Rabbit Cell signaling 
c-Myc                                                   1:1000 Rabbit Santa Cruz 
Biotechnology 
Wnt 5a\b 1:1000 Rabbit Cell signaling 
Notch1 1:1000 Rabbit Abcam 
Notch2 1:1000 Rabbit Abcam 
Notch3 1:1000 Rabbit Abcam 
Axin2    1:1000 Rabbit Cell signaling 
APC 1:1000 Rabbit Cell signaling 
LPR6 1:1000 Rabbit Cell signaling 
Anti-beta actin   1:1000 Mouse Cell signaling 
Anti-alpha tubulin 1:1000 Mouse Abcam 
Table 18: List of primary antibodies used for western blot 
Table 19: List of secondary antibodies used for western blot 
 
3.2.8 Tumour sphere assay 
 
CD44+MKN45 cells were resususpended in serum-free RPMI 1640 culture medium 
containing 1% N2 supplement, 2% B27 supplement, 1% antibotic-antimycotic 
(Invitrogen) 20 ng/ml human FGF-2 (Sigma, Saint Louis and 100 ng/ml EGF 
(Invitrogen) containing either the control with DMSO or different concentrations of 
GSI (2.5µM, 5µM and 15μM), and plated in 96-well ultra-low attachment plates 
(Corning, USA) at 2,000 cells per well. 7–10 days later, plates were analyzed for 
tumoursphere formation and were quantified using an inverted microscope 
(Olympus) at 100X, 200Xmagnification. The size of the tumoursphere formed under 
each condition was also considered during quantification. 
 
 
 
 
Target Working dilution Manufacturer 
Anti-mouse IgG 
peroxidase conjugated 
 
1:10000 Amersham 
Anti-rabbit IgG peroxidase 
conjugated 
 
1:10000 Amersham 
Mouse TrueBlotTMHRP-
conjugated anti-mouse IgG 
(clone eB144/7A7) 
1:15000 
 
Bioscience 
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3.2.9 Immunohistochemistry 
 
Tissue sections were fixed in 4% formalin (Sigma-Aldrich) overnight, stored in PBS 
and embedded in paraffin. For immunohistochemistry slides were deparaffinised 
using an oven at 550ºC overnight (GE Healthcare Limited) and rehydrated in 
decreasing ethanol concentrations (6 min to 100%, 95%, 75%, 40% ethanol) (Merck) 
and then rinsed three times for 3-5 minutes with 1xPBS. Antigen retrieval was 
performed by heating the slides in pressure cooker with Antigen Unmasking Solution 
(Vector Laboratories, Inc.) The slides were then washed in PBS and incubated for 10 
minutes in 1% H2O2 (Sigma-Aldrich, USA), rinsed with PBS, and incubated 1 hour in 
100µl of blocking solution (5% normal serum þ 0.3% Triton X-100, Vector 
Laboratories, Inc.) at room temperature protected from light. Hybridization with the 
100µl primary antibody in 1X PBS was carried out overnight at 4°C.  The next day the 
sections were washed three times for 3 minutes each in 1×PBS then 100µl of 
secondary antibody was incubated for 1 hour at room temperature, light protected. 
The sections were then rinsed three times for 3 minutes with 1 × PBS, 100 µl of ABC 
reagent (Vectastain ABC Kit, Vector Laboratories) was added to the tissue and 
incubated for one hour at room temperature followed by three times in 1 × PBS rinse 
subsequently. 300 ul freshly prepared Vector DAB substrates (Peroxidase Substrate 
Kit DAB, Vector Laboratories) were applied to the tissues and waited up to 3 minutes 
until a desired DAB background was obtained. Subsequently, the slides were 
immersed in distilled water to stop the DAB reaction. This was followed by 
counterstaining with hematoxylin for 1 minute and subsequent rinsing with water. 
Slides were counterstained with hematoxylin (Merck) and dehydrated in 40%, 70%, 
90%, and 100% ethanol. Finally, slides were cleared with Rhothistol (Roth) and 
mounted with Permount Toluene Solution (Fisher Scientific).   
 
Staining intensity was graded as negative staining (0); defined as missing nuclear 
and/or cytoplasmic staining even when using high amplification (40x). Weak staining 
(1); defined as nuclear and/or cytoplasmic staining visible at high magnification (40x) 
only. Moderate staining (2) is defined as nuclear and/or cytoplasmic staining visible at 
medium magnification (10x-20x amplification). Strong staining (3) is defined and/or 
cytoplasmic staining already visible at low magnification (2.5x-5x amplification). The 
intensity of staining was scored independently by two investigators. Ten high power 
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fields were randomly selected from each slide for scoring expression of CD44 and 
HES1 staining.  Positive staining was defined as grade 2-3 and negative as 0-1. 
 
Table 20: Primary antibody for immunohistochemistry. 
 
Table 21: Secondary antibody for immunohistochemistry. 
3.2.10 Immunofluorescence 
 
CD44+MKN45 cells were cultivated on cover slips prior to immunofluorescence. The 
cover slips were washed with 1XPBS three times and were fixed with 4% 
formaldehyde. Then the cells were washed with PBS three times again and 
permeabilized with 1% Triton-X for 5 minutes. Cells were blocked with 10% Bovine 
Serum Albumin (BSA, Sigma) for 30 minutes and afterwards incubated at 37°C for 1 
hour with the 100µl of primary antibody in 1xPBS . After primary antibody incubation 
the cells were washed three times in PBS. This was followed by incubation of the 
cells with 100µl of secondary antibody for 30 min at room temperature in dark. Cells 
were washed with 1X PBS and were stained with 4,6-diamidino-2-phenylindole 
(DAPI, Sigma) in order to reveal cell nuclei. Finally, stained cells were analyzed using 
a fluorescence microscope (Leica DMI 6000 B microscope) to measure the CD44 
and HES1 expression. 
 
Target Working dilution Source Manufacturer 
Anti CD44 antibody  1:100 Rabbit Novus Biotechnology 
Hes1 antibody 1:100 Rabbit Abcam 
NCL – ki67P 1:100 Rabbit Novocastra, Leica 
Target Working dilution Manufacturer 
Anti-Rabbit IgG (H+L) 
biotinylated  
 
1:200 Vector laboratories 
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Quantification for TMAs was performed using ImageJ freeware and expressed per 
mm² of total tissue area. For the analysis of CD44, Hes1, Hes1 + CD44 staining, the 
positive stained cells where chosen from six randomly selected areas for each tumour 
(using a scale of 100µM).  Staining intensity was graded as negative staining (0); 
defined as missing staining (40x). Weak staining (1); defined as staining visible at 
high magnification (40x) only. Moderate staining (2) is defined as staining visible at 
medium magnification (10x-20x amplification). Strong staining (3) is defined already 
visible at low magnification (2.5x-5x amplification). The staining intensity was 
calculated as a percentage of total tissue area. The intensity of staining was scored 
independently by two investigators. Positive staining was defined as grade 2-3 and 
negative as 0-1. 
 
Table 22: Primary antibody for immunofluorescence/Flow cytometry. 
Table 23: Secondary antibody for immunohistochemistry. 
3.2.11 CD44 cell sorting and flow cytometry (FACS) 
 
3.2.11.1 Sample preparation and sorting. 
CD44 populations were sorted from human gastric cancer cell line MKN45. Cells 
were washed in ice cold 1X PBS at 500 rpm for 5minutes. This was followed by 
blocking 100 μl of blocking buffer (5% BSA/PBS) for 30 minutes on ice. Cells were 
centrifuged at 500 rpm for 5 minutes at 4°C. Cells were then incubated with 100µl of  
primary antibody in 1 mM EDTA/1%BSA/PBS for 25 minutes on ice. Cells were 
resuspended with 100µl of ice-cold 1 mM EDTA/1%BSA/PBS and centrifuged at 500 
Target Working dilution Source Manufacturer 
Anti CD44  antibody 1:100 Rabbit Abcam 
Hes1 antibody 1:100 Rabbit Abcam 
Target  Working dilution Manufacturer 
Anti mouse FITC 1: 200 Dianova 
 
Anti Rabbit Alexa Flour 594 1:200 Life Technologies 
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rpm for 5minutes. After centrifugation the cells were stained with 100µl of secondary 
flurochrome conjugated antibody for 20 minutes in dark. The stained cells were 
washed twice with 1 mM EDTA/1%BSA/PBS, centrifuged at 500 rpm for 5 minutes 
and the cell pellet was suspended in 200 μl of 1mM EDTA/1%BSA/PBS prior to 
analysis. The stained cells were measured with FACS Calibur (Becton Dickinson 
Immunocytometry Systems). KP3 cells were used as a positive control as previously 
published (84). 
After preparation of the samples, the cells were subjected to FACS sorting. CD44+ 
and CD44- population of MKN45 cells were collected under sterile conditions in 
different sterile facs tubes. The sorted cells were washed twice with 1XPBS by 
centrifugation at 500 rpm for 5  minutes at 40ºC and were added to the plates 
containing complete culture medium (RPMI 1640+Glutamax)supplemented with 20% 
FCS and penicillin / streptomycin (100 units/ml). 
3.2.11.2 In vivo handling of CD44 sorted MKN45 cells 
 
For in vivo experiments, 6×104 sorted cells were resuspended in PBS/Matrigel 
(mixture 1∶1 volume, BD Biosciences) and were injected subcutaneously in to the left 
and right flank of 6-week-old female nude mice (NMRI-nu/nu). For in vitro 
experiments the sorted cells were taken into cell culture and were treated with control 
(DMSO) or GSI inhibitor (2.5µM, 5µM, 15µM) (Calbiochem). Sorted CD44+ and 
unsorted cells were used for the following experiments: proliferation assay, migration 
assay, invasion assay, tumour sphere assay, immunoblotting, apoptosis assay, 
nuclear cytoplasmic extraction, immunofluorescence staining and siRNA transfection.  
 
3.2.11.3 Isolation of mononuclear cells from blood for FACS analysis 
 
One ml of blood in Heparin was collected from control or GSI treated xenografts from 
the heart. The blood was further subjected to Ficoll-Plaque PLUS (Amersham 
Bioscience) density gradient centrifugation at 500rpm for 30 minutes in order for 
mononuclear cells to be isolated (MNC). Concentrated MNCs were harvested from 
the interface with the help of a disposable Pasteur pipette by placing the sample on 
ice. The isolated cells were washed twice in ice-cold PBS, then centrifuged for 30 
minutes at 500 rpm. Isolated MNCs were processed for flow cytometric analysis 
using staining protocol for FACS analysis as mentioned above. In addition, 10ml 
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blood from healthy donors (n=4) and patients with untreated gastric cancer (n=3) was 
collected and further processed like mentioned.  
 CD44 and HES1 detection was routinely performed with the primary antibody 
omitted to control for background staining. Double-staining (CD44 and Hes1) was 
compared to parallel cells stained for CD44 or HES1 alone. Cells were routinely 
sorted twice and reanalyzed for purity (XDP, Beckman-Coulter). 
3.2.12 Tumour sphere forming assay 
 
 CD44+MKN45 cells were suspended in serum-free culture medium DMEM 
containing 1% N2 supplement, 2% B27 supplement, 1% antibotic-antimycotic 
(Invitrogen, Germany) 20 ng/ml human FGF-2 (Sigma, Saint Louis, USA), and 100 
ng/ml EGF (Invitrogen, Germany) containing either the control with DMSO or different 
concentrations of GSI IX (2.5µM, 5µM and 15μM), and plated in 96-well ultra-low 
attachment plates (Corning, USA) at 2000 cells per well. 7–10 days later, plates were 
checked under the microscope for tumoursphere formation. Tumourspheres were 
analyzed and quantified using an inverted microscope (Olympus, Germany) at 100X, 
200X magnification. The microscopic images of the tumourspheres were taken on 
the day of quantification. During quantification the difference in size of the 
tumourspheres between the DMSO control and GSI treated cells were also 
considered. For each well the average count of the tumourspheres formed were 
taken into consideration for quantification. 
 
3.2.13 Adhesion assay 
 
Collagen type IV (Bovine, Sigma) and Hyaluronic acid (bovine, Calbiochem) were 
diluted from stock concentration of (1mg/ml) to (5µg\ml) using 1X PBS. In a 96 well 
plate 100µl\well of the substrate was added into their respective well in triplicate. The 
96 well plate containing the substrates were allowed to settle for 2 hours at room 
temperature under the culture hood. After 2 hours the substrates were removed from 
the wells. Each well was washed two times with 200µl of 1XPBS. After washing 
200µl of blocking buffer (RPMI 1640+Glutamax containing 10% FCS) was added to 
the wells and incubated for 30 minutes at 37ºC, 5% CO2  incubator. After blocking the 
wells were again washed with 200µl of 1XPBS. 5x104 cells/100µl with DMSO or GSI 
IX (2.5, 5 and 15µM) was added to their respective wells in triplicates. The 96 well 
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plate was incubated overnight at 370C, 5% Co2 incubator. Next day the plate was 
inverted upside down and incubated at 37oC, 5% Co2 for atleast 1.5 hours. After 
incubation the plate was tilted at an angle of 450 and the medium was transferred to 
a fresh 96 well plate into their respective wells (DMSO or GSI IX) treated. The fresh 
96 well plate contains the suspension cells under each condition whereas the other 
plate contains the adherent cells.  Using WST-1 reagent (Roche, Darmstadt) the 
number of suspension cells and adherent cells in the respective plates under each 
condition (DMSO or 2.5, 5 and 15µM GSI IX) was calculated and compared.  
3.2.14 Nuclear cytoplasmic extraction 
 
1.5x 106 CD44+MKN45 cells were treated with control DMSO or different 
concentrations of GSI (2.5µM, 5µM and15μM) for 48 and 96 hours and subjected top 
nuclear cytoplasmic extraction using NE-PER™ Nuclear and Cytoplasmic Extraction 
kit (Thermo Fisher Scientific, USA) and following the kit instruction manual. The cells 
were collected for nuclear cytoplasmic extraction in 1xPBS. 100µl of ice cold CER I 
reagent and 5.5µl of CERII reagent and 50µl of NER reagent (the reagents were 
provided in the kit) was added to the cell pellet followed by vigorous vortexing of the 
tube at highest setting for 15 seconds (volume ratio CER I: CER II at 100:5.5 µl). 
After vortexing the tube was incubated for 15 minutes on ice followed by 
centrifugation for 5 minutes at 1000 rpm. The supernatant was immediately 
transferred to a pre chilled tube and stored at -20°C, this tube contains the 
cytoplasmic fraction. The insoluble pellet was resuspended in 50µl of NER buffer. 
The sample was vortexed for 5 seconds followed by centrifugation for 5 minutes at 
1000 rpm. Immediately after centrifugation the supernatant was transferred to 
another fresh prechilled tube and stored at -20°C. This tube contains the nuclear 
fraction. Extracts were stored at -20°C until used.  
 
3.2.15 Small interfering RNA (siRNA) transfection 
 
To knock-down Notch1 and CD44 in MKN45 cells we used synthetic pre designed 
siRNA for Notch1 (Ambion Thermo Fisher scientific) and CD44 (Ambion Thermo 
Fisher scientific, USA). MKN45 cells were plated at a concentration of 5x103 cells/ml 
in 6 well plate and were transfected with transfection reagent containing control 
siRNA (Ambion Thermo Fisher scientific, USA) at a concentration of 10nM, 25nM, 
30nM and 50nM or Hes1/CD44 siRNA for 24hours, 48hours and 72hours using 
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Hiperfect transfection reagent (Qiagen,USA). The tubes containing siRNA were 
diluted to working concentration in Hiperfect transfection reagent and were vortexed 
shortly for five seconds followed by incubation for 15 minutes in room temperature 
prior to addition to the cells.  After incubation the mixture was added drop by drop to 
the cells. The cells were kept in the incubator at 370C according to the time desired 
(between 48 to 96 hours) The transfection efficiency was judged based on western 
blot analysis at 48 and 96 hours. 
3.2.16 Patient samples and tissue microarray (TMA) 
 
Fresh human tissues were collected from patients who underwent endoscopic 
procedure at the Medizinische Universitätsklinik Tübingen, Germany. Tissues were 
representing normal gastric mucosa (N), inflammation (G) and gastric cancer. Tissue 
microarrays composed of 269 human gastric cancer specimens were obtained from 
the Institute of Pathology, Medical School Hannover (MHH), Germany.34 The clinical, 
pathological and survival data were also obtained from the same patients. Tissue 
microarrays composed of 269 human gastric cancer specimens were obtained from 
the Institute of Pathology, MHH, Germany. The clinical, pathological and survival 
data were also obtained from the same patients (93). 
 
3.2.17 Animals and Invivo treatment 
 
For in vivo experiments, 6×104CD44 sorted cells were resuspended in PBS/Matrigel 
(mixture 1∶1 volume, BD Biosciences) in ice and were injected subcutaneously in to 
the left and right flank of 6-week-old female nude mice (NMRI-nu/nu). NMRI-nu/nu 
female nude mice were obtained from Charles River Laboratories International 
(Sulzfeld, Germany). In total 10 mice were used for MKN45 xenograft experiments. 
CD44+ MKN45 cells (1x106) were subcutaneously injected into each flank for each 
mouse. Mice were assigned into treatment groups (5 mice per group). Tumour size 
was measured by caliper and tumour volume was calculated using the following 
formula: Tumour volume V= [(ð\6) x (Lenght) x (Width
2
)]. When tumour volume 
reached a size of 100mm3, mice were treated intraperitoneally with GSI (10 
mg/kg/body weight) or control (PBS) for four times per week followed by three days 
rest. The drug was prepared by dissolving in PBS with 10% DMSO. The compound 
was stored at ambient temperature and resuspended prior to use in order to ensure 
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that no particles settled at the bottom. Health status and treatment side effects were 
inspected every day. After 4 weeks of therapy when the control mice tumours 
reached a size of 1000mm3 all mice were sacrificed, tumours were snap frozen for 
protein analysis and fixed in 4% formalin for histology. The weight of the tumours for 
two groups (control and GSI treated) was also measured.  The mice used in this 
study were maintained in the animal care of Medizinische Universitätsklinik Tübingen 
(UKT), Germany. All experimental protocols were reviewed and approved by 
institutional guidelines for animal care of UKT and Baden Württemberg (protocol no: 
M 11/12). 
 
3.2.18 Statistical analysis 
 
All the experiments were repeated 3 times. Data were presented as mean ± standard 
deviations (41). The results were analyzed using software Graphpad prism version 
5.0 (GraphPad Software, San Diego, CA) and SPSS Version 11.0 (SPSS, Chicago, 
USA). The tests include one-way ANNOVA analysis of variance, student´s t-test 
along with Bonferroni post test and paired, unpaired t-tests. The overall survival 
analysis using Kaplan-Meier curves were analysed by log rank test. For all tests, a P 
value of <0.05 was considered statistically significant. 
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4. Results 
4.1 CD44 and Hes1 are effectively upregulated in both gastric cancer cell lines, 
human tissues and also show an influence on patient survival. 
CD44 is an established cell surface marker for CSCs and is also known to play an 
important role in gastric cancer progression. Therefore, in order to target these 
population of tumour cells positive for CD44 known to be the main candidates for 
therapy resistance,we performed some initial screening. 
 
First we analysed five different gastric cancer cell lines to validate the expression of 
CD44 by using Flowcytometry. The cell lines analysed for initial screening were 
MKN45, SNU-1, 2313287, NCI-N87. MKN45 is a human gastric cancer cell line 
derived from a 62 year old female having poorly differentiated adenocarcinoma 
(65).SNU (Seoul National University) cell lines are derived from various cancer 
patients in  
Korea since 1982.  SNU1 is one of the gastric carcinoma cell lines derived during this 
study in Korea. (66) For our present study SNU 1 cell line was used. KATO III is a 
human gastric carcinoma cell line developed in vitro from a pleural effussion of a 55 
year old male patient (66). NCI-N87 cell line is derived from well-differentiated human 
gastric carcinoma. This cell line exibhits some true features of gastric epithellium 
(68). 
 
Flow cytometric analysis showed MKN45 -65%, Kato III – 18.4%, 2313287 – 8.7%, 
SNU – 4.5%. of CD44 positive cells. Amongst this panel of five different gastric 
cancer cell lines analysed, MKN45 showed the highest population of CD44 + cells 
(65%) as compared to other gastric cancer cell lines. In contrary SNU-1 cell lines 
showed the lowest percentage (4.5%) of CD44+ cells. Since Notch and wnt-beta-
catenin pathways are known to be the two most important pathways associated with 
gastric CSC maintenance, therefore specific targeting of these two pathways in 
gastric cancer treatment could be of interest. Next we wanted to analyse the 
expression level or activation of these pathways in our selected MKN45 cells. 
Therefore we checked the expression level of Hes1 (downstream of Notch pathway) 
and wnt 5a/b (the non canonical ligand of wnt and is associated with the 
agressiveness of the tumour) by western blot. We reconfirmed the expression of all 
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the three targets (CD44, Hes1, wnt 5a/b) in these five cell lines and among all of 
them in accordance with the FACS data MKN45 showed relatively high expression of  
 
all the targets. (Figue 10 A, B). Thus from the screening we selected MKN45 for our 
in vitro experiments as this cell line showed significant expression of all the three 
targets (CD44, Hes1 and wnt5a/b).  
 
Important to our study  gastric cancer patients have shown high expression level of 
wnt5a/b and the expression levels were well correlated to poor survival of these 
patients (55, 104).Therefore in accordance with the above mentioned study, we also 
wanted to analyze the expression of the same markers (CD44, Hes1, wnt 5a/b ) in 
fresh human gastric cancer tissues (Normal-N, Gastritis-G, Gastric cancer – GC) 
(figure 10C). Our western blot results clearly show the highest expression of 
specifically  CD44, Hes1 and also wnt 5a/b in gastric cancer tissues as compared to  
normal, gastritis human samples. The lowest expression of the targets were 
observed in normal tissues. We further wanted to analyze the coexpression of Hes1 
and CD44 in the same population of CD44+ MKN45 cells. In order to achieve CD44+ 
MKN45 cells, these cells were subjected to sorting using FACS for CD44. FACS 
analysis of the CD44 sorted MKN45 cells also showed a considerably high 
expression of Hes1 (79.2%) in comparison to the CD44- population of MKN45 cells 
(22%) (Figure 10 D). The kaplan-meier survival analysis of 269 patients showed a 
strong correlation between CD44 and Hes1 double positivity with overall survival. 
Patients with both CD44 and Hes1 double positivity showed lower survival as 
compared to patients with Hes1 and CD44 double negetive (P=0.004) (Figure10 F). 
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Figure 10: CD44 and Hes1 expression in gastric cancer cell lines and human tissues. 
 
A.Table showing the relative percentage of expression of CD44 from a panel of 5 different 
human gastric cancer cell lines. Western blot analysis of the targets (CD44, Hes1, wnt 5a/b) in  
B.human gastric cell lines and C. human gastric tissues (N-Normal, G-Gastritis, GC-Gastric 
cancer). Beta-actin was used as a loading control. D. FACS analysis of CD44+ and CD44- 
MKN45 cells showing a significant increase in Hes1 expression in CD44+ population compared 
to the CD44-. E. Bar graph representing the staining intensity of CD44 and HES1 in 269 
human gastric cancer analysed tissues. (*GC tumour issues showing both moderate and 
strong staining for HES1 or CD44 were considered to be positive whereas tumour tissues 
showing both weak and negative staining were considered to be negative) F. Kaplan-Meier 
overall survival curve for GC patients categorised by Hes1 and CD44 expression showing a 
significant difference. (**P<0.005) 
 
We also performed immunohistochemistry and immunofluorescence in human gastric 
cancer tissues derived from 269 patients. 86% of the gastric cancer patient tissues 
showed a considerably high expression of both CD44 and Hes1 (Figure 11 A, B and 
C). Importantly the CD44 positivity was mainly confined to the cell membrane and the 
cytoplasm (cytoplasmic staining) whereas positive staining for Hes1 was mainly 
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confined to the nucleus (nuclear staining) in the same gastric cancer tissues. The 
staining intensity was determined as explained in material and methods section. 
Notably, specifically in immnunofluorescence staining of human gastric cancer 
tissues we not only observed positivity for CD44 and Hes1in the gastric tissues but 
also, a strong coexpression \ colocalisation of CD44 and Hes1 (Figure 11B, C and 
D).   
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Figure11: Expression of CD44 and Hes1 in human gastric cancer tissues. 
 
A.Immunohistochemical staining images of gastric cancer tissues showing the coexpression 
of CD44 and Hes1 with different staining intensities (strong, moderate, weak).Representative 
B C 
D 
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pictures were taken using light microscope under (10X and 20X magnification. 
Immunofluorescence images of human GC tissues for CD44 (green), Hes1 (red) and 4,6-
diamidino-2-phenylindole (DAPI) (blue) and merged (yellow). Representative images for B. 
positive staining C. Negative staining for CD44 and Hes1. Photographs were taken using 
confocal microscopy. D. Bar graphs representing the quantification of Hes1, CD44, CD44 
and Hes1 (positive vs. negative) of 269 patients. *GC tumour tissues showing both moderate 
and strong staining for Hes1 or CD44 was considered to be positive whereas tumour tissues 
showing both weak and negative staining were considered to be negative ***P<0.001. 
 
Next we wanted to examine if CD44, Hes1 double postivity can have on overall 
prognostic outcome or influence on patient survival.  Therefore, in order to verify this 
we did a survival analysis of the patients from which the tumour tissues were derived 
showing positivity for both the targets (CD44+Hes1+) (Figure 12 D). Interestingly, the 
analysis showed significantly lower or impaired survival in patients with double 
positivity for CD44 and Hes1 (P=0.004). We also observed differences in overall 
survival in patients with either CD44 or Hes1 positivity (P=0.004). Hes1 positivity 
showed a higher impact on overall survival, compared to CD44 single positive group 
of patients. Thus, the overall survival analysis shows that eventhough Hes1 single 
positive group of patients show lower survival than CD44 single positivity but CD44 
and Hes1 double positive group of patients had the highest impact on overall survival 
being the lowest with a median survial of 35 to 40 months. A gender and age based 
study of the patients was also performed in order to confirm that these two factors 
might have an influence on the double positivity (CD44 and Hes1) in the patients. We 
did observe a higher expression of Hes1 and CD44 double positivity in older group of 
gastric cancer patients with an age reference range of 60 to 70 years. Unfortunately, 
no such difference or impact on incidence of double positivity was observed 
depending on the gender (male vs. female) (Figure 12 A and B).  
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Figure 12:  Age and Gender based incidence of CD44 and Hes1 positivity in human 
gastric tissues and its impact on overall survival. 
Bar graph representing the staining intensities for CD44 and Hes1 according to A. Age and 
B. Gender (male vs. female) in a panel of 269 human GC tissues. * GC tumour tissues 
showing both moderate and strong staining for Hes1 and CD44 were considered to be 
positive whereas tumour tissues showing both weak and negative staining were considered 
to be negative C. Kaplan-Meier survival analysis of GC patients categorised by Hes1, CD44, 
Hes1 and CD44 expression  (P<0.005). 
 
Therefore, all together our results show that both human gastric cancer cell lines and 
tissues have a relatively considerable higher amount of double positivity and 
colocalisation for both CD44 and Hes1. CD44 and Hes1 double positivity can also act 
as a prognostic marker for gastric cancer patients as a strong correlation was 
observed in patients with double positivty (CD44+Hes1) to the overall impaired 
survival. Important for our studies the gastric cancer cell line MKN45 showed positivity 
for CSC marker CD44 and also showed activation of both the pathways Notch (Hes1 
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positive) , wnt-beta-catenin pathways (wnt5a/b positive) known to be associated with 
CSC maintenance. Therefore, targeting Notch and wnt-beta-catenin pathways via 
CD44 could be of therapeutic interest in gastric cancer. 
4.2GSI IX acts an effective anti proliferative, anti-migratory and anti-invasive 
agent and also induces considerable apoptosis in CD44+ MKN45 cells. 
To target CD44 and also to observe th effect of CD44 inhibition of MKN45 human 
gastric cancer cell line we used GSI IX inhibitor. Since, GSI IX is known to be 
associated with inhibition of Notch pathway, we tried to analyse if GSI IX treatment 
could also influence CD44 expression (CD44 being a CSC marker is also associated 
with the activation of Notch pathway, important for maintaining the self renewal of 
CSC population). Thus, we first tried to test the overall impact on CD44 inhibition 
using GSI IX on three main aspects associated with cancer growth: proliferation, 
invasion, migration ability of CD44+ MKN45 cells.  
 
Based on our previous screening we selected MKN45 as the candidate cell line for 
our further in vitro experiments as it showed significant activation of all the three 
targets (CD44, Hes1 and wnt5a/b). Uncontrolled cell growth or proliferation is one of 
the key mechanisms of cancer cells leading to cancer progression. Therefore, in 
order to inhibit proliferation of MKN45 gastric cancer cells we used GSI IX on 
CD44+MKN45 cells. From our previous publication Palagani et al., 2012 (74) we 
chosethree specific dosages (2.5uM,5uM and 15uM) of GSI IX for treating MKN45 
cells. Therefore, to verify if these three dosages can inhibit proliferation of CD44+ 
MKN45 cells and that GSI IX specifically targets CD44 as a mode of action for 
inhibiting proliferation of CD44+MKN45 cells we performed a time course cell 
proliferation assay. CD44 positive sorted population of MKN45 cells were treated 
with GSI (2.5uM,5uM and 15uM)  for 24,48,72 and 96 hours using WST-1 reagent. 
The graph showed a significant inhibition of CD44+ MKN45 cells in a dose and time 
dependent manner (Figure 13 A, B). The highest inhibition of CD44+ MKN45 cells 
was observed at 15uM of GSI IX at 96 hours of treatment. Importantly, GSI IX 
effectively inhibited proliferation of only CD44+ population of MKN45 cells as CD44- 
cells. In order to ensure that GSI IX is an effective drug for gastric cancer treatment 
we compared the anti-proliferative effect of GSI IX to 5FU. 5FU is a standardised 
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chemotherapeutic drug widely used for treating gastric cancer patients worldwide. 
Proliferation assay was performed using both CD44+ and CD44- MKN45 cells and 
were treated with 5 FU in the highest dosage used for GSI IX treatment (15uM). The 
highest dosage of GSI IX (15uM) was also used for 5FU in order to compare the 
effectiveness of the drug at the highest possible dosage used for the study. A similar 
time course proliferation curve was obtained. The result clearly showed that 5FU 
treatment was more effective in inhibiting the growth of CD44- population of MKN45 
cells as compared to the CD44+ (Figure 13 C and D). Thus, this result clearly shows 
that GSI IX treatment has strong target specific anti-proliferative effect on CD44+ 
MKN45 as compared to the standardised treatment option of 5FU. Morover, GSI IX 
effectively inhibits the growth of CD44+ gastric CSC in contrast to 5FU, thus reducing 
the chances of tumour relapse associated with CSC. 
 
 
 
Figure 13: GSI IX effectively inhibits proliferation of CD44+ MKN45 cells 
specifically via targeting CD44+ CSC. 
A.Line graph representing the cell proliferation of CD44+ MKN45 cells treated with GSI (2.5, 
5 and 15uM) or DMSO for 4 days. B. Corresponding light microscope images of cell 
proliferation assay on day 4 showing the anti-proliferative effect of GSI IX on CD44+ CSCs.  
A B 
C D 
                                                                                                                                                           Results 
 
80 
 
Graph showing the comparison of target specific anti-proliferative effect of 15uM 5FU and 
15uM GSI on C. CD44- population D. CD44+ population of MKN45 cells. 5FU showed 
significant anti-proliferative effect only on CD44- population as compared to CD44+ MKN45 
cells. GSI IX effectively inhibits proliferation of both CD44+ and CD44- MKN 45 cells. 
 
Target specific action of GSI IX on CD44+ was strongly observed on 
immunofluorescence staining of CD44+ MKN45 cells for DAPI, CD44 and Hes1 
treated with DMSO or GSI (2.5uM, 5uM and 15uM) (Figure 14A). 
Immunofluorescence staining clearly showed an effective inhibition or lower 
expression of CD44 and Hes1 single or colocalised expression in CD44+ MKN45 
cells by GSI IX.The strongest inhibition was observed under 15uM of GSI IX 
treatment as compared to the control. Thisresult revealed that GSI IX inhibits 
proliferation of MKN45 cells via specifically targeting CD44+ CSC present in MKN45 
cells.GSI IX mediated downregulation of CD44 also showed effective inhibition of 
Hes1 (Notch downstream).  
                                                                                                                                                           Results 
 
81 
 
 
Figure 14: GSI IX effectively inhibits CD44 and Hes1 expression in the same 
population of CD44+ MKN45 cells. 
A.Immunofluorescence images for staining of 4,6-diamidino-2-phenylindole (DAPI, blue), 
CD44 (green), Hes1 (red) in CD44+ MKN45 cells treated with DMSO or GSI (2.5, 5 and 
15uM). Photographs were taken using confocal microscopy. 
 
Invasion and migration are the two main important, higly integrated and multi-step 
processes involved in cancer progression or metastasis. An effective therapeutic 
approach is considered to be optimal if the tested drug shows potential as an anti- 
proliferative, anti-invasive and anti-migratory agent on cancer cells. Therefore, our 
next step was to determine if GSI IX treatment caneffectively inhibit invasion and  
migration of CD44+ MKN45 cells. Therefore, we first performed migration or wound 
healing assay. The CD44+ MKN45 cellswere treated with GSI (2.5uM, 5uM and 
15uM) or DMSO and was subjected to wound healing analysis. Significant (P=0.001) 
inhibition of migration was observed under GSI IX treament in CD44+ gastric cancer 
A 
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cells compared to the control Migration is usually analysed by measuring the relative 
closure of the wound in CD44+ MKN45 cells under GSI IX treatment in comparison to 
the control. The highest anti-migratory effect was observed under 15uM of GSI IX 
treatment in comparison to the DMSO control. (Figure 15 A). 
 
Next we wanted to examine invasion using matrigel coated invasion chambers after 
GSI IX treatment of CD44+ MKN45 cells. GSI IX treatment effectively inhibited the 
invasion of CD44+ MKN45 cells in concentration dependent manner (P<0.001) 
(Figure 15 B). The most effective inhibition was observed under 15uM GSI IX 
treatment. Thus, our results show that GSI IX treatment effectively inhibits migration 
and invasion of CD44+gastric cancer cells. 
 
GSI IX treament effectively inhibited proliferation and also induced considerable cell 
death. Therefore, we wanted to analyse the exact mechanism by which GSI IX Notch 
inhibitor is inducing cell death on the CD44+ MKN45 cells.  Apoptosis also known as 
programmed cell death is a systemic process in which cells commit suicide by 
activating an intracellular porgramme. Apoptosis is the one of the major key 
mechanisms or process by which cells undergo death by activating an intracellular 
proteolytic cascade (72). Importantly, apoptosis is often considered to be one of the 
main mechanisms involved incancer cell death. So, we analysed apoptosis using 
Annexin V/PI staining and measured the amount of apoptotic cells using FACS. 
(Annexin V is usually used in conjunction with another vital dye PI. Viable cells with 
intact cell membrane exclude PI therefore are PI negative whereas cells with 
distorted cell membranes are permeable to PI therefore, dead cells are PI positive. 
Early apoptotic cells are Annexin V+ but PI- whereas late apoptotic or nearly dead 
cells are both Annexin V+ and PI+). We noted that GSI IX treatment showed 
significantly (P>0001) high induction of apoptosis as compared to the DMSO group 
(Figure 16 A). The highest induction of apoptosis of CD44+ MKN45 cells was 
observed at 96 hours under 15uM of GSI IX treatment. Thus, the results 
highlightedapoptosis as the main mechanism by which GSI IX induces cell death in 
CD44+ MKN45 cells. 
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Figure 15: GSI effectively inhibits migration, invasion and induces apoptosis in CD44+ 
MKN45 cells.A.Bar graph representing the Migration index of CD44+ CSCs after DMSO or 
GSI (2.5uM, 5uM and 15uM) treatment. Photographs to analyse the relative wound 
A 
B 
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healingwere taken at 0hour and 24 hours from the time the scratch was made (20X 
magnification). B. Bar graph representing the invasion index of CD44+ CSCs after DMSO or 
GSI (2.5, 5 and 15uM) treatment. Light microscope pictures (20X magnification) were taken 
and invasion index was calculated  
 
 
 
 
 
 
 
 
 
 
Figure 16: GSI effectively inhibitsinduces apoptosis in CD44+ MKN45 cells. 
A. Apoptosis was quantified using Annexin V/propidium iodide (PI) staining using flow 
cytometry to CD44+ MKN45 cells treated with DMSO or GSI (2.5uM, 5uM and 15 uM) for 48 
and 96 hours***(P<0.001).B. Western blot showing the clevage of PARP under GSI 
treatment (2.5uM, 5uM and 15 uM). Actin was used as a loading control. 
 
Recent studies showed that poly(ADP-ribose) polymerase (PARP) is required for 
inducing apoptosis in several cells. Cleavage of PARP catalysed by caspase-3 which 
leads to the depletion of NAD (a PARP substrate) and ATP which are important for 
 A. 
 
B. 
A. 
Full length PARP 
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later events of apoptosis. The importance of cleavage of PARP in apoptosis initiation 
was first investigated and proved in human osteosarcoma cells (73). Thus we also 
wanted to check for cleavage of PARP as a marker for apoptosis in GSI IX treated 
CD44+ MKN45 cells. As Annexin V/PI staining showed a considerable induction of 
apoptosis therefore, we thought checking of the status of PARP by western blot in 
CD44+ MKN45 cells treated withDMSO or GSI IX (2.5 uM, 5 uM and 15uM) could be 
of interest. Western blot analysis showed a higher expression in clevage of PARP 
under GSI treatment specifically under 15uM of GSI IX in CD44+ MKN 45 cells at 96 
hours (Figure 16 B). As expected the western blot results of PARP as a marker for 
apoptosis showed us a similar result in accordance with our previous result of 
apoptosis measurement by FACS. These results thus reconfirmed apoptosis as one 
of the key mechanisms involved in induction of cell death by GSI IX treatment in 
CD44+ gastric CSCs.  
Therefore, GSI IX not only targets CD44+ population of MKN45 cells resulting in 
inhibition of invasion, migration but also induces high amout of apoptosis. 
4.3 GSI IX treatment effectively impairs tumoursphere formation of CD44+ 
MKN45 cells. 
CSCs harbor the potential to form non-adherent spheres or tumourspheres under 
low attachment conditions. This phenomenon of CSCs is also known as the de novo 
tumour formation.  Therefore, it would be of interest to see if GSI IX treament can 
influence tumoursphere formation of CD44+ MKN45 cells. GSI IX (2.5uM, 5uM and 
15uM) treatment showed effective inhibition of tumour sphere formation in CD44+ 
MKN45 cells as compared to the DMSO control (P>0.001). Notably, the size of the 
spheres formed by the control cells were relatively larger than that formed by the 
CD44+ MKN45 cells under GSI IX treatment (Figure 17A, B and C). The size of the 
spheres reflect that GSI IX treatment inhibits the tumour sphere forming potential of 
CD44+ gastric CSCs which cause lesser accumulation of cells to form 
tumourspheres which are smaller in size compared to the untreated cells. 
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Figure 17: GSI inhibits tumoursphere formation in CD44+ MKN45 cells. 
 
A.Representative images of tumourspheres formed by control (DMSO) and 15uM GSI 
treated CD44+MKN45 cells. Light microscope pictures of tumourspheres formed after GSI 
treatment in comparison to the DMSO control at 96 hoursB. CD44+MKN45 cells were treated 
with DMSO or GSI (2.5uM, 5uM and 15 uM) for 96 hours. C. Bar graph showing the 
quantification of the tumourspheres formed by CD44+ MKN45 cells after DMSO or GSI 
treatment (*** P<0.001) 
A 
B 
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4.4GSI IX effectively blocks CD44 mediated adhesion in CD44+ MKN45 cells. 
CD44 belongs to the family of adhesion molecules involved in the cell to cell and cell 
matrix interaction. CD44 adhesion molecule under certain conditions also initiates 
metastatic spread of tumour cells (49). Adhesion could also be one of the probable 
mechanism achieved by CD44 for tumour spread. Therefore, we tested the effect of 
GSI IX treatment on the adhesive capacity of CD44. Adhesion assay results showed 
an effective increase in suspension cell population under GSI IX treatment (2.5uM,  
5uM and 15uM) (20-25%; 55-60%; 80-85% respectively) in comparison to the DMSO 
treated control cells (40-45%). Hyaluronic acid (HA) is an important ligand for CD44 
binding. Thus, for adhesion assay HA coated plates were used and the population of 
suspension and adherent cells in CD44+ MKN45 cells was measured under different 
conditions. CD44+ MKN45 cells showed decrease in the population of adherent cells 
resulting in increase in suspension cells specifically under 15uM of GSI IX treatment 
as compared to control. This shows that GSI IX treatment effectively targets and 
inhibits CD44 expression resulting in inhibition of the role of CD44 as a adhesion 
molecule in CD44+ gastric cancer cells. Importantly, CD44+ MKN45 cells showed an 
increase in adhesion cell population due to increased affinity of CD44+ cells to bind 
tothe only ligand HA. Therefore, GSI IX treatment effectively targets and inhibits 
CD44 adhesion molecule associated with gastric cancer progression (Figure 18 A,B 
and C). 
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Figure 18: GSI effectively inhibits adhesion of CD44+ MKN45 cells 
Bar graphs representing the amount of adherent and suspension cells present in CD44+ 
MKN45 cells after A. 2.5uM GSI, B. 5uM GSI and C.15uM GSI treatment under with or 
without hyaluronic acid (HA, the ligand for CD44 binding) (*** P<0.005). 
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4.5 GSI IX effectively inhibits Notch1 mediated concomitant activation of Notch 
and wnt-beta-catenin pathways in CD44+ MKN45 cells. 
Notch pathway activation involves activation of several Notch receptors like Notch 1, 
Notch 2 and Notch 3. Since our western blot and immunofluorescence results clearly 
show the activation of Hes1 (a downstream of Notch) in CD44+ MKN45 cell line as 
well as in human gastric cancer tissues therefore, we wanted to see which Notch 
receptor is important to activate the Notch pathway in CD44+ gastric CSCs. Mainly 
we were interested in identifying the downstream targets that might play a role in 
Notch mediated gastric cancer progression and impaired upon GSI IX treatment. For 
this the CD44+MKN45 cells were treated with DMSO or GSI IX (2.5uM, 5uM and 
15uM) and were subjected to western blot analysis. Interestingly, the western blot 
results showed a relative downregulation of specifically Notch1 after GSI IX 
treatment in a dose and time dependent manner whereas, Notch 2and Notch 3 
remained relatively unchanged (Figure 19 A). Moreover, the intracellular domain of 
Notch1 (NICD) also showed a relative downregulation compared to the DMSO 
control under GSI IX treatment. c-Myc is an oncogene that is overexpressed in 
majority of human cancer and also contributes to about 40% of all tumours. Several 
studies specifically the study by Herranz Det al.,2014 (69) showed that in certain 
malignancies like T cell lymphoblastic leukeamia Notch1 causes a c-Myc mediated 
feed forward loop which results in c-Myc dependent cellular growth and metabolism 
in cancer. Several reports also showc-Myc as a direct downstream of Notch1 in 
cancer. Since Notch 1 was observed to be downregulated by GSI IX in CD44+ 
gastric cancer MKN45 cells,we also checked for c-Myc status before and after GSI 
IX treatment in these cells. By western blot analysis we observed a relative 
downregulation or inhibition of c-Myc after GSI IX treatment. The highest inhibition 
was observed in 15uM of GSI IX treatment at 96 hours. Hence, this shows that GSI 
IX might inhibit Notch signaling in gastric cancer CSCs via inhibition of Notch1 and 
its downstream c-Myc in CD44+ MKN45 cells. Therefore, Notch1 and c-Myc might 
mediate a feedback loop not only in gastric cancer progression but also in GSI IX 
mediated treatment in CSCs (69). Notch1 and c-Myc also has several common 
downstream effector proteins like  Ras-related C3 botulinum toxin substrate 1 
(Rac-1) associated with cell motility during carcinogenesis, Akt (Serine/threonine 
kinase also known as protein kinase B) responsible for cell survival in cancer, extra  
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cellular signal regulated kinase regulates (ERK) cell proliferation, signal transducer 
and activator of transcription 3 (Stat3) is known to play as an oncogene and promote 
cancer via activation of several cancer associated pathways.Therefore,using western 
blot we wanted to confirm the inhibition of these common downstream effector 
proteins in GSI IX treated CD44+ MKN45 cells (Figure 19 B). Thus, the phospho-
form of these downstreams which are known to play important role in cell regulatory 
pathways (Rac1, AKT, Erk, STAT3) were effectively downregulated under GSI IX 
treatment  whereas, the full forms of these effector proteins remained unchanged 
after treatment. Therefore, GSI IX treatment inhibits Notch1 and c-Myc which results 
in complete inhibition of common important downstreams like Erk, Akt etc in GSI IX 
treatment in CD44+ gastric cancer cells.  
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Figure 19: GSI effectively inhibits Notch and wnt-beta-catenin crosstalk in CD44+ 
MKN45 cells. 
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CD44+ MKN45 cells were treated with DMSO or GSI (2.5uM, 5uM and 15uM) for 48 hours 
and 96 hours A. GSI treatment was evaluated on Notch signaling downstream effector 
proteins (Notch1, Notch 2, Notch3, NICD, Hes1) by western blotting.B.GSI effect on 
probable candidates involved in Notch and wnt-beta-catenin crosstalk in CD44+ gastric 
cancer cells (CD44, c-Myc, Stat3, p-Stat3, Akt, p-Akt, Erk, p-Erk, Rac1) analysed by western 
blotting. C. Western blots showing the effect of GSI treatment on  wnt-beta-catenin pathway 
downstreams in CD44+ MKN45 cells (Beta-catenin, wnt 5a/b, Axin 2, LPR6, APC). Actin was 
used as a loading control. 
 
Since Notch and wnt-beta-catenin pathways are the two main players involved in 
maintenance of CSCs, we next wanted to analyse whether wnt-betacatenin pathway 
can also be inhibited via GSI in CD44+ MKN45 cells. Therefore, we checked for 
some common wnt-beta catenin pathway downstreams like Axin-related protein 
(Axin2) , APC (adenomatous polyposis of the colon), LPR6 after GSI IX treatment.  
InWnt pathway the formation of a multi-protein complex mediated by Axin 2 
consisting of APC, beta-catenin, glycogen synthase kinase 3-beta, LPR6 results in 
degradation of beta catenin. Thus, this complex is important for regulation of beta 
catenin in wnt pathway (76).In order to understand the status of wnt-beta-catenin 
pathway in CD44+ MKN45 after GSI IX we checked the above mentioned wnt 
downstreams using western blot. Western blot analysisclearly showed a relative 
inhibition of the downstreams of wnt-beta-catenin pathway (Wnt 5a/b, beta-catenin, 
Axin2, APC, LPR6) under GSI IX treament in CD44+ MKN45 cells (Figure 19C). 
Thus our data clearly shows that the co activation of both Notch and wnt beta-
catenin pathway in CD44+ gastric CSCs. Moreover, these results also proove that 
GSI IX treatment effectively inhibits the concomitantly active Notch and wnt-beta-
catenin pathways in CD44+ gastric CSCs via inhibition of common downstream 
effectors. Importantly, this concomitant activation of both the pathways in gastric 
CSCs might be mediated via Notch-1 and c-Myc (Notch -1 activates c-Myc which in 
turn activates a series of downstream effector proteins also common to wnt-beta 
catenin pathway). 
4.6GSI IX partially influences EMT in CD44+ MKN45 cells. 
Epithelial Mesenchymal Transition (EMT) is a critical process during tumour 
progression and malignant transformation. During EMT epithelial cells acquire 
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mesenchymal phenotype thus endowing the cancer cells with invasive and 
metastatic potential. Many oncogene pathways including Notch and Wnt-beta-
catenin induce EMT process.EMT is commonly characterised by the down regulation 
of epithelial marker E-Cadherin and upregulation of mesenchymal marker N-
cadherin during cancer progression (70). We therefore, wanted to asses the impact 
of GSI IX treatment on EMT markers specifically E and N cadherin. Western blot 
analysis showed that GSI IX treatment partially influenced the EMT process as E-
cadherin remained relatively unchanged whereas, N-cadherin was partially 
downregulated specifically under 15uM of GSI IX treatment in 96 hours (Figure 20 
A). Therefore, GSI IX treatment has a partial impact on EMT process in CD44+ 
gastric CSCs.  
 
 
 
 
Figure 20: GSI IX partially influences EMT in CD44+ MKN45 cells. 
CD44+ MKN45 cells were treated with DMSO or GSI (2.5uM, 5 uM and 15 uM) for 48 hours 
and 96 hours. Influence of GSI on EMT markers (E cadherin, Ncadherin) was analysed by 
western blotting on CD44+ MKN4 cells. Actin was used as a loading control. 
 
4.7 GSI IX blocks the growth of CD44+ gastric cancer cells via inhibition of 
Notch1 mediated Notch and wnt-beta-catenin crosstalk in MKN 45 cells. 
In order to understand the exact mechanistic approach of GSI IX in inhibition of 
CD44+ CSCs, and moreover to understand the pivotal role of Notch and CD44 in 
gastric cancer progression we performed siRNA mediated silencing of  both CD44 
and Notch1. Western blot was used to analyse the effect of siRNA mediated 
silencing of Notch1 and CD44 on Notch, wnt-beta-catenin pathway and the common 
downstream effector proteins involved in mediating the crosstalk both with or without 
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15uM of GSI IX treatment. Firstly siRNA mediated silencing of CD44 led to the 
downregulation of Hes1, p-Erk, p-Akt, Rac1, p-Stat3, c-Myc,wnt 5a\b, CD44, Notch1 
(Figure 21 A). These results were in accordance with the effect observed after GSI 
IX treatment. Notch1 siRNA treatment showed by immunoblotting similar down-
regulation of CD44, Hes1, p-Erk, p-Akt, Rac1, p-Stat3, c-Myc, wnt 5a/b and beta 
catenin, these results were also in accordance to the effect observed under GSI IX 
treatment (Figure 21 B).Therefore, these results clearly show that GSI IX mediated 
approach for inhibition of gastric CSCs is mainly mediated by targeting the CD44+  
CSCs which in turn results in the Notch1 mediated inhibition of Notch wnt-beta-
catenin crosstalk involved in the maintenance of gastric CSCs. Therefore, siRNA  
mediated silencing of CD44 and Notch1 not only demonstrated the status and 
importance of  these two targets in mediating the Notch wnt-beta-catenin crosstalk in 
gastric CSCs but also highlighted the probable mechanistic approach exhibited by 
GSI IX in CD44+ gastric cancer cells. 
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Figure 21: GSI inhibits Notch and wnt-beta catenin crosstalk in CD44+ MKN45 cells via 
Notch 1 
siRNA mediated silencing of  A. CD44  B. Notch1 to confirm the effect of GSI on Hes1, p-
Erk, p-Akt, RAC1, Notch 1, c-Myc, Stat3, P- Stat3, wnt 5a/b, beta-catenin by immunoblot.  
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β-actin was used as a loading control. C. Complete inhibition of nuclear translocation of 
beta-catenin was observed after GSI treatment in CD44+CSCs using western blot.Alpha-
tubulin was used as loading control. 
 
A major hallmark for the activation of the wnt-beta-catenin pathway is the 
accumulation of beta-catenin in the cytoplasm. wnt regulates beta catenin levels 
through various mechanisms as mentioned in Bryan T et al.,2009(71). One of the 
main mechanisms involved in the activation of this pathway is via the formation of 
APC-Axin2-GSK3B complex which can induce activation of various Wnt downstream 
targets via translocation of beta catenin to the nucleus. Importantly the status of beta 
catenin is important to determine the off set (accumulation in the cytoplasm) or on 
set (translocation to the nucleus) status of wnt-beta-catenin in CD44+MKN45 cells. 
Therefore, to see the inhibition effect of GSI on wnt-beta-catenin pathway we 
performed western blot using the nuclear and cytoplasmic extracts of CD44+ MKN45 
treated with DMSO or GSI IX (2.5 uM, 5 uM and 15uM). Our western blot results 
clearly showed that 15uM GSI IX effectively inhibited translocation of beta catenin to 
the nucleus (Figure 21C). Thus, inactivation of wnt/beta-catenin pathway was 
observed after GSI IX treatment as, GSI effectively inhibited the nuclear transloction 
of beta cateninin CD44+ MKN45 cells. The western blots clearly showed higher 
accumulation of beta-catenin in the cytoplasmic extract than the nucelar extract 
under GSI IX treatment in contrast to the controls. Therefore, GSI IX effectively 
inhibits not only the Notch pathway but also the wnt-beta-catenin pathway in CD44+ 
gastric CSCs.  
4.8GSI IX effectively inhibits tumour growth in CD44+ MKN45 xenograft 
tumours. 
Important to our study we next wanted to examine the in vivo effect of GSI IX on 
CD44+ xenograft tumours. In order to achieve this each xenograft mice was injected 
with CD44+ MKN45 cells on both flanks. Treatment protocol and method used to 
establish xenograft tumour in nude mice is explained in Materials and Methods 
section. Tumou r progression is one of the biggest challenge faced during cancer 
treatment therefore, inhibition of tumour growth is utmost importance in cancer 
therapy. In order to achieve this we treated CD44+xenograft tumours with GSI IX 
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(10mg/kg four times per week) or placebo (PBS). In a total of 4 weeks of GSI IX 
treatment we observed a significant (P>0.001) difference in tumour size between the 
control (placebo treated) and GSI IX treated groups. GSI IX treatment effectively 
inhibited CD44+ gastric tumour growth in xenografts (Figure 22 A,C and F). 
Histological analysis of resected xenograft tumours showed higher incidence of 
necrosis in the GSI IX treated group as compared to the placebo group (Figure 22B). 
Therefore, GSI IX treatment induces necrosisto inhibit tumour growth in vivo in 
CD44+ MKN45 xenograft tumours.Moreover, GSI IX treated xenograft tumours 
showed significantly (P<0.005) lower tumour weight as compared to the control 
group (Figure 22 E). Importantly, GSI IX treated tumours showed a stable body 
weight during the treatment tenure as compared to the placebo treated xenograft 
group (Figure 22 D). 
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Figure 22: GSI inhibits CD44+ CSC tumour growth. 
 
A.Pictures of mice taken at 4 weeks. The left mouse is treated with vehicle, the right mouse 
with GSI IX. The arrows heads representthe respective xenograft tumours. B. 
Representative H & E staining pictures of corresponding tumours (10X and 20X 
F 
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magnification) showing necrosis under GSI treatment.C. Tumour growth curves after GSI 
and placebo treatments (both right and left flank tumours were taken into consideration).The 
curves clearly show the effective inhibition of tumour growth after GSI IX treatment.Bargraph 
representing the difference in D.mouse weight and E. tumour volume under GSI and vehicle 
treament for four weeks. Differences were considered as statistically significant when the P-
value was<0.05 and non significant “n.s.” when the P-value was>0.05. Error bars show 
standard deviation.F. Macroscopic images of control and GSI treated explanted xenograft 
tumours. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 23: GSI treatment effectively inhibits the proliferative of CD44+ xenograft 
tumours. 
A. Ki67 staining images of corresponding tumours under 10X and 20X magnification, 
showing effective downregulation of the anti proliferative marker after GSI treatment. 
B.Graph representing the quantification of Ki67 staining of the xenograft tumours under 
placebo and GSI treatment(* P<0.05). 
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Ki67 is an anti-proliferative marker and therefore we analysedthe expression level of 
Ki67 by immunohistochemical staining on both GSI IX and placebo treated resected 
xenograft tumours. Tumours under GSI IX treatment showed considerable decrease 
in Ki67 expression in treated tumours as compared to the placebo group (Figure 23 
Aand B). Thus, the staining clearly showed that GSI IX has a strong anti-proliferative 
effect on gastric tumour growth. In order to understand the target specificity of GSI IX 
treatment on xenograft tumours we also analysed the expression level of CD44 and 
Hes1 by immunohistochemistry/immunofluorescence. The stainings clearly showed 
a considerable decrease in expression of both the targets CD44 and HES1 under 
GSI IX treatment ( Figure 24 A, B and C).  
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Figure 24: GSI inhibits gastric cancer xenograft tumour growth by specifically 
targeting the colocalised population of CD44+ and Hes1+ cells. 
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Representative immunofluorescence images for xenograft tumours for CD44 (green), Hes1 
(red), CD44 and Hes1 merged (yellow) and 4,6-diamidino-2-phenylindole (DAPI, blue) for 
CD44, Hes1 stainings of A. Control B. GSI treated xenograft tumours. C. Graphs 
representing the quantification of the immnufluorescence staining intensities for CD44, Hes1, 
Hes1+ and CD44+ for placebo and GSI treated xenograft tumours. (**P<0.005) 
 
Western blot analysis of the xenograft tumours showed an effective decrease in all 
the common downstream targets like CD44, Hes1, Notch1, c-Myc,wnt 5a/b, beta-
catenin etc. The common downstream effector proteins involved in the crosstalk of 
both Notch and wnt-beta-catenin pathway in CD44+ gastric cancer like p-Erk, p-
Stat3, Notch, Rac1 were effectively inhibited (Figure 25A and B). Full forms of Stat3, 
Akt, Erk remained relatively unchanged under GSI IX treatment. For Notch pathway 
we checked for Hes1, Notch1, c-Myc etc by western blotting to confirm the inhibitory 
effect of GSI IX on Notch pathway via CD44. We also wanted to check the inhibition 
effect of GSI IX on wnt-beta-catenin pathway. Therefore, using western blotting we 
checked for some main stream and downstreams for wnt-beta-catenin pathway. Our 
western blot results clearly showed the effective downregulation of wnt-beta-catenin 
pathway downstreams like Axin2, APC and LPR6 under GSI IX treatments (Figure 
25 B). Since Axin2,APC, LPR6 are involved in the formation of complex  that helps in 
the translocation of beta-catenin to the nucleus therefore downregulation of these 
effector proteins shows effective inhibition of wnt-beta-catenin pathway by GSI IX 
inhibitor in CD44+ gastric xenograft tumours. All the above mentioned inhibitory 
effect of GSI IX on Notch and wnt-beta-catenin crosstalk in vivo where in accordance 
with the effect observed in vitro. As mentioned earlier EMT is associated with tumour 
invasion. Using western blot we also checked the expression of EMT markers like  
E- cadherin and N-cadherin in xenograft tumours. GSI IX treated tumours influenced 
an effective upregulation of epithelial marker E-cadherin and downregulation of 
Mesenchymal marker N-cadherin (Figure 25B). The western blot clearly showed an 
effective inhibition of EMT process by GSI IX treatment in CD44+CSC xenograft 
tumours.  
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         Figure 25: GSI inhibits the growth of CD44+ xenograft tumour growth via concomitant 
inhibition of Notch and wnt-beta-catenin pathway. 
A.The expression of CD44, Hes1, wnt 5a/b, Erk, p-Erk, Akt, p-Akt, Stat3, p-Stat3 and NICD 
of GSI and placebo treated xenograft tumours by western blotting. B. Notch1, Rac1, Axin2, 
APC, LPR6, c-Myc, E-cadherin, N-cadherin and beta catenin expression levels were also 
analysed by western blots for GSI and placeo treated tumours. Beta-actin was used as a 
loading control. C. Cleavage of PARP was also analysed using western blot for GSI and 
placebo treated xenograft tumours.Actin was used as a loading control. 
 
To reconfirm the induction of apoptosis by GSI IX treated xenograft tumours as  
observed in vitro, we performed western blot analysis of PARP. Immunoblot showed 
cleavage of PARP in GSI treated tumours as compared to the control or placebo 
treated xenograft tumours (Figure 25 C). Therefore, GSI IX also induces 
considerable cell death in xenograft tumours which is in accordance with our in 
C 
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vitrofindingsthat also highlights induction of cell death involved in GSI IX mediated 
treatment. Thus, our results clearly supports that GSI IX treatment effectively inhibits 
the concomitant activation of both the pathways Notch and wnt-beta-catenin by 
targeting CD44 in CD44+ CSC xenograft tumours. Moreover,ourin vivo data also 
supports induction of apoptosis by GSI IX treatment similar to in vitro data.  
4.9CD44+ and Hes1+ double positive cells could be a new target for gastric 
cancer. 
CD44 is also used as a cell surface marker for early T cell development in the 
thymus and also for tracking memory T cells.Notably, Hes1 is also found to be 
involved in the development of T cells (17). To establish CD44 as a CSC marker for 
gastric cancer we selected CD44+ alongwith HES1+ as a double positive marker to 
specifically target gastric CSC. Usage of double positive marker (CD44+ and Hes1+) 
also reduces the chance of targeting CD44 present in normal human blood. 
Therefore, in order to understand the specificity of GSI IX treatment in vivoon CD44+ 
CSC xenograft tumours we performed FACS analysis using mononuclear cells 
isolated from the blood collected from both the groups (Control and GSI IX treated 
xenografts). The FACS analysis clearly showed an effective downregulation under 
GSI IX treatment of the double positive (CD44+ and Hes1+) cells in xenograft blood 
(35 to 40%) compared to the control/placebo group blood (75 to 80%) (Figure 26 B 
and C). Moreover, we also compared the percentage /  incidence rate of (CD44+ and 
Hes1+) in the blood of normal mice to that of CD44+ CSC xenografts (Figure 26 A). 
This was done in order to reduce the chances of off target effects on the normal 
population of CD44+ and Hes1+ cells expressed in normal blood due to the presence 
of T lymphocytes. FACS analysis of monocytes isolated from the blood of a normal 
mice (without tumour disease)revealed that only 20% of cells were found to be 
CD44+ and Hes1+ double positive. This suggests that the GSI IX treatment shows a 
probable specific approach only towards CD44+ and Hes1+ double positive cells as 
the average count of double positive cells in normal blood is same as that observed 
in the blood of the GSI IX treated xenografts (Figure 15D).  Notably blood from 
human patients as well as control xenografts showed a relatively higher expression 
of CD44+and Hes1+ double positive cells which highlights that CD44+ and 
Hes1+double positive cells can be an attractive target for GSI IX treatment. 
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Moreover, the decrease in the expression of CD44+ and Hes1+ double positive cells 
shows specificity for GSI IX treatment. Importantly, the average count of CD44+ and 
Hes1+double positive cells remains constant as observed in the blood of  normal 
mice to that of GSI IX treated xenografts. 
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Figure 26: GSI inhibits CD44 and Hes1 double positive in CD44+ xenografts. 
FACS analysis of double positive cells (CD44+ and Hes1+) in monocytes isolated from 
A.Normal mice B. Placebo treated and C.GSI treated CD44+ xenografts (blood from 
C57BL/6 mice were used for normal mice). D.Graph representing the quantification of CD44+ 
and Hes1 double positive cells analysed by FACS in blood collected from three different  
groups (Normal, control and GSI ) mice. 
 
We also wanted to check the expression of CD44+ and Hes1+ double positive cells in 
the blood of gastric cancer patients in comparison to normal individuals.  FACS 
D 
31.4 66.6 83.0 
A C B 
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analysis of mononuclear cells isolated from the blood of both normal and gastric 
cancer patients showed a significant (P<0.005) increase of double positive cells in 
the blood from gastric cancer patients (65 to 70%) in comparison to that of normal 
individuals (20 to 22%) (Figure 27 A, B and C). Therefore, the FACS analysis of 
human blood clearly potentiates the effectiveness or the possiblity of using CD44+ 
and Hes1+ double positive cells as an attractive target for gastric cancer treatment.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 27: Expression levels of CD44+ and Hes1+ double positive are higher in gastric 
cancer patients compared to normal individuals. 
44 + Hes1 
CD44 + Hes1 
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FACS analysis showing the percentage of double positive cells (CD44+ and Hes1+) in the 
mononuclear cells of blood isloated from A. Normal healthy individuals and B. Gastric 
cancer patients. C. Graph representing the quantification of the relative percentage of 
expression of CD44 and Hes 1 double positive cells in the mononuclear cells of blood 
collected from patients (gastric cancer patients vs normal individuals) (**P<0.005). 
 
Taken together, FACS analysis data clearly shows CD44+ and Hes1+ double 
positivity as a probable futuristic marker for gastric cancer treatment. The decrease 
in double positives (CD44+ and Hes1) under GSI IX treatment highlights these cells 
as an attractive target for GSI IX mediated treatment of CD44+ CSC in gastric 
cancer. 
 
Therefore, our invitro and invivo results suggest a strong anti cancer effect of GSI IX 
on gastric cancer. A strong correlation between in vivo and patient data reflects 
CD44+ and Hes1+ double positive cells as a probable futuristic marker for gastric 
cancer treatment. GSI IX effectively targets CD44+ CSCs and inhibits gastric cancer 
growth via concomitant blockage of Notch and wnt-beta-catenin pathways. Thus, 
GSI IX proves to be an effective, target specific therapeutic option for gastric cancer. 
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5. Discussion and outlook 
5.1 Targeting CSCs for gastric cancer treatment 
CSCs are one of the primary candidates involved in tumour relapse and resistance 
to chemo or radiotherapy (54). Targeting CSCs using specific cell surface marker to 
inhibit CSC mediated resistance of tumour cells has been a debatable approach in 
the field of cancer treatment. Therefore, selective targeting of CSC population could 
be of immense interest in cancer cure. Moreover, identification of CSC using specific 
cell surface markers has been an effective tool towards targeting these candidates of 
tumour resistance (55).  
CD44 is widely recognised as a pleotropic molecule expressed on the surface of 
stem cells and is also known to be involved in tumour metastasis. Thus, targeting 
CSC using CD44 as a cell surface marker could be an effective way towards CD44 
associated tumour growth ( 54, 55) . 
CD44 +
Tumor inhibition
CD44-
Tumor relapse
CD44 +
CSC survival
 
Figure 28:Targeting CD44 gastric cancer initiating cells  via GSI IX (Gamma secretase 
inhibitor IX) to inhibit gastric cancer. 
The diagram showing the tumour relapse with general anti cancer drugs in comparison to 
CD44 target specific inhibitors like GSI IX thus leading to complete inhibition of tumours 
(adapted from 81). 
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Several signaling pathways like Notch, Hedgehog,wnt-betacatenin etc has been 
identified as activators of CD44 receptor (60, 61, 74, 75). Important to our present 
study CD44 levels has been identified to be upregulated in a wide variety of cancers 
like pancreatic, breast, colon and also in gastric cancer (84, 85). CD44 
overexpression was found to be associated with poor prognosis and lower survival in 
CD44+ gastric cancer patients in comparison to the CD44- population (86). In 
addition to gastric cancer, studies by Hong et al.,2009 (87) showed that in pancreatic 
cancer patients CD44 expression was associated with histological grade and poor 
prognosis (86). The role of CD44 in chemotherapeutic resistance was always 
debatable due to conflicting results obtained in different studies  (87, 89, 94). Studies 
showed that metastatic colorectal cancer patients treated with oxaliplatin or 5FU 
(standard chemotherapies used for cancer treatment) showed no strong correlation 
between CD44 expression and chemotherapeutic resistance or overall patient 
outcome (35). In contrary to the previous study, in vitro colon cancer cells showed a 
significant decrease in CD44 expression under treatment with oxaliplatin or 5FU and 
also incombination with curcumin (88). Moreover, Jaggupilli A et al.,2012 (90) 
showed expression of CD44 in colonic tumours thus, reflecting CD44 as one of the 
main candidates associated with tumour growth and metastasis. Interestingly, 
increased proliferation of CD44+ pancreatic cancer cells upon gemcitabine treatment 
also showed a strong correlation between CD44 expression and chemotherapeutic 
resistance(89, 87). Overall, these studies reflect an important role of CD44 in cancer 
progression, and it also potrays that the dual contradictory role of CD44 is highly 
dependent on the cancer types. 
 
Gastric cancer is known to be the second most common cause of cancer related 
death worldwide. New modes of gastric cancer treatments are of utmost need. Our 
study mainly potentiates targeting of CD44using gamma secretase inhibitor IX (GSI 
IX) as an effective approach in gastric cancer treatment. Though CD44 is known to 
play a contradicting role in colon cancer yet regarding gastric cancer development 
CD44 has also shown to be an effective marker associatedwith CSC mediated 
cancer progression (91, 51). GSI IX has already been assesed as a potential 
inhibitor in several cancers including pancreatic cancer etc. Studies by Palagani et 
al.,2012 showed thatCD44+/ EpCAM+ pancreatic cancer cells are inhibited by GSI 
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and the decrease of CD44+ cells correlates with response to chemotherapy in a 
panel of gastrointestinal cancer (76, 93).  
 
In this current study we validated the role of CD44 in gastric cancer and also showed 
GSI IX as an effective therapeutic treatment option to target CD44+ CSC. CD44 
mediated CSC maintenance is regulated by some of the major cancer associated 
pathways. The role of Notch in gastric cancer has been explored for many years. 
Amongst various pathways involved in CSC maintenance Notch and wnt-beta-
catenin pathways are found to be the two most important pathways associated with 
CSC mediated cancer progression (94, 95). However, the involvement of CD44 and 
Notch signaling as a new target in gastric cancer progression and specific targeting 
of  CD44+ CSCs by GSI still remained to be explored as an alternative therapeutic 
approach in gastric cancer.  
5.2 CD44, Hes1 as a prognostic marker for gastric cancer patients 
We first studied the expression of CD44 in a panel of 269 gastric cancer patients and 
correlated the expression of CD44 to overall patient survival. Patients with CD44 and 
Hes1 double positivity showed an overall impaired survival in comparison to CD44 
and Hes1 negative population. Survival analysis identified the potential role of CD44 
and Hes1 double positivity in gastric cancer prognosis.Our data also demonstrated a 
significant expression of CD44 and Hes1 in tissue and blood samples of gastric 
cancer patients. Considering the role of wnt pathway in CD44 mediated CSC 
maintenance, we also analysed the expression of wnt 5a/b in gastric cancer patient 
samples. Interestingly, effective co-activation/co-expression of wnt 5a/b was also 
observed in the same samples showing upregulation of both CD44 and Hes1. 
Therefore, activation of both Notch (Hes1) and wnt (wnt 5a\b) pathway in CD44+ 
gastric cancer patient samples was also observed. Sequential increase in expression 
of the three targets (CD44, Hes1, wnt 5a/b) was specifically observed being highest 
in gastric tumours in relation to inflammation or normal patient samples. Additional 
analysis of patient blood in comparison to normalindividuals also reflected an 
upregulation of CD44 and HES1 double positivity from being 22% in normal to 66% 
in gastric cancer patients. Thus,analysis of patient samples mainlyfoccussed on the 
prognostic role of Hes1 and CD44 double positivity as an effective marker. 
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Additionally, existence of concomitantly active Notch and wnt pathway in CD44+ 
gastric cancer patient tumours was also verified.  
5.3 Inhibition of Notch pathway in CD44+ CSC in gastric cancer 
Inhibition of Notch has been regarded as an effective therapeutic strategy in various 
cancer studies. Previous studies have shown effective inhibition of Notch pathway in 
pancreatic cancer cells by GSI IX (90). Amongst the various novel strategies 
available for gastric cancer treatment, inhibition of Notch pathway is also considered 
as an important target. Studies have shown that alteration of Notch pathway led to 
the development of various human malignancies including gastric cancer (96, 97, 
98). Therefore, we tested the inhibitory effect of GSI IX in CD44+ MKN45 cells to 
show that Notch signaling might contribute to the maintenance of CD44+ gastric 
CSC. MKN45 cells reflected diffuse type of gastric cancer as it is established from 
poorly differentiated, diffuse type adenocarcinoma of the stomach (65). GSI IX 
treatment showed effective inhibition of all important cell regulatory processes 
associated with cancer growth like proliferation, migration, invasion, adhesion (CD44 
also acts as an important cell adhesion molecule involved in tumour progression) 
and tumour sphere formation (important characteristic feature of CSC) in CD44+ 
MKN45 cells in a time and dose dependent manner. Further coactivation of CD44 
and Hes1 in the same population of CD44+ MKN45 cells was observed. Importantly,  
effective inhibition of Hes1 via targeting of CD44 under GSI IX treatment in CD44+ 
gastric CSCs was achieved. GSI IX treatment also showed effective induction of 
apoptosis as a key role mechanism to induce cell death in CD44+ gastric CSC. 
These results clearly highlighted inhibition of Notch signaling by GSI IX as a potential  
treatment approach for CD44+ gastric cancer. 
5.4 GSI might influence Epithelial-to-mesenchymal transition (EMT) via RAC1 
in CD44+ CSC 
EMT is an important collective event which results in conversion of epithelial 
adherent cells to independent fibroblastic cells possesing migratory or invasive 
properties (54). Previous studies have shown contribution of Notch signaling to 
acquisition of EMT processes (84). Interestingly, GSI IX treatmentshowed a low or 
partial inhibitory effect on EMT markers like E-cadherin, N-cadherin etc. 
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Incontrary,GSI IX effectively inhibited EMT associated processes like migration and 
invasion in CD44+ MKN45 cells. This contradiction can be attributed to the role of 
RAC1 played in modulation of epithelial cell plasticity in cancers through matrix 
metalloproteinases (MMPs). Since GSI treatment showed effective inhibition of 
RAC1 thus it can be assumed that probablyGSI mediates/ regulates EMT via RAC1 
through MMPs(99). Threfore, GSI mediated inhibition of epithelial plasticity in gastric 
cancer through MMPs could be of futuristic importance. Moreover, this strategy could 
also open up new ways of EMT inhibition through MMPs in gastric CSCs, but further  
investigations are required for confirmation of this proposed alternative.  
5.5 Dual inhibition as an effective strategy for gastric CSC 
Abberant activationof wnt beta-catenin pathway hasbeen found to be associated with 
certain areas of gastric cancer progression and is also known to play important role 
in regulating tumour growth, metastasis etc. Importantly, a strong correlation was 
observed between wnt1, CD44 expression and grade of gastric cancer patients (100, 
101). Moreover, important to our study Western blot analysis of the CD44+ MKN45 
showed a similar activation of both Notch and wnt along with CD44 in accordance 
with the findings of the patient’s samples (102, 103). Therefore, we further analysed  
and showed concomitant activation of both Notch and wnt-beta-catenin pathway in 
CD44 positive MKN45 cells. Moreover, we also further highlighted on GSI IX 
mediated dual inhibition of both Notch and wnt betacatenin pathways in these CD44+ 
gastric cancer cells. GSI IX treatment not only showed effective inhibition of Notch 
pathway and its downstreams like Hes1, Notch 1 etc but also effectively inhibited the 
wnt-beta-catenin pathway via downregulation of common wnt downstreams like 
LPR6, Axin2, wnt 5a/b etc. Therefore, our findings firstly focussed on the activation 
of Notch and wnt-beta-catenin pathway in CD44+ gastric CSCs. Secondly, we also 
proposed in this study the existence of a probable crosstalk between Notch and wnt-
beta-catenin signaling cascades mediated by CD44 (using some common 
downstream effector proteints like c-Myc, Akt, Erk etc associated with important cell 
regulatory processes resulting in cancer progression) in CD44+ gastric CSCs. 
Finally, we also identified GSI IX as a potential drug which can concomitantly inhibit 
both the pathways (Notch and wnt-beta-catenin) associated with gastric CSC 
maintenance via effective targeting of CD44. Therefore, reducing all chances of 
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tumour relapse or resistance to standard chemotherapeutic regimes associated with 
CSCs.  
5.6 Notch1 might influence important crosstalks in CD44+ CSC 
Several studies have shown an effective or critical role of Notch receptors in gastric 
cancer development. Yeh et al.,2004 (104)showed that Notch 1 activaton leads to 
the development of COX2 dependent gastric cancer progression(34). Moreover, 
study by Yeh et al.,2009(104)demonstrated the role of Notch 1 in gastric CSC 
regulation (103). In contrast to the mentioned studies Notch4 has also been 
attributed to play an important role in gastric carcinogenesis (105). Qian et al.,2015 
(106) reported an important role of Notch 4 involved in the activation of wnt-beta-
catenin pathway in gastric cancer (106). Furthermore, Kang et al., 2012 (107) 
described the expression of Notch3 and Jagged2 in association with GC 
development (107). Overall, these studies highlights the contradictory importance of 
Notch receptors (Notch 1, 2 3 and 4) in gastric cancer progression. However, our 
results demonstrated the role of Notch 1 in CD44 mediated gastric CSC 
maintenance. The western blot analysis showed Notch 1 to be an effective and 
important mediator of Notch and wnt-beta-catenin crosstalk in CD44+ gastric CSC. 
siRNA mediated silencing of CD44 and Notch 1 further strengthened the important 
regulatory role played by Notch 1 in CD44 mediated maintenance of gastric CSC via 
activation of Notch and wnt-beta-catenin pathways. Notch1 as well as Notch2 are 
already known to be critical for the metaplastic transition of gastric epithelial cells 
(108). Hence, our study represented a significant extension of theprevious studiesin 
gastric cancershowing that Notch1 is the main target and critical for the interaction 
between Notch signaling and GC CD44+ cells. Our findings clearly showed Notch 1 
dependent interaction in CD44+ gastric CSCs compared to Notch 2  or 3 specifically 
under GSI treatment. In addition, silencing of CD44 and Notch1 resulted in a 
significant downregulation of multiple target genes that could play a regulatory role in 
exhibiting the Notch 1 mediated dual crosstalk in gastric CSCS. 
Amongst colon, breast and lung tumours overexpression or mutation of c-Myc has 
also been observed in gastric cancer. However the role of c-Myc in gastric 
carcinogenesis needs to be explored more in detail (109). c-Myc known to be an 
important oncogene and relative to our study, a direct downstream of Notch1 
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(109,110, 111) might also be important in mediating the crosstalk by acting as an 
effective  downstream effector protein connecting CD44 and Notch, wnt-beta-catenin 
pathways in gastric CSCs. Sawant S et al.,2016 showed an effective independent as 
well as combinational role with CD44 in oral cancer (112). Moreover, a regulatory 
reciprocal role has also been observed between CD44 and Epidermal Growth Factor 
Receptor (EGFR) via c-Myc in gastric cancer (110). Contrastingly GJ Yoshida 
etal.,2014showed an inverse realtionship between CD44 and c-Myc in gastric cancer 
cells (111). Our western blot analysis showed c-Myc as an effective connective 
effector for the crosstalk followed by effective inhibition under GSI IX treatment. 
Moreover, silencing of CD44 also showed a direct regulatory impact on c-Myc 
expression in gastric CSC. Therefore, all together c-Myc might act as a connective 
effector between CD44, Notch1 and wnt-beta-catenin pathway in gastric cancer.  
 
 
 
Figure 29: Schematic representation of GSI IX mediated dual inhibition of Notch and 
wnt-beta-catenin pathways in CD44+ gastric cancer. 
                                                                                                                          Discussion and outlook 
114 
 
Diagram representing the concomitant inhibition of Notch and wnt-beta-catenin pathway in 
CD44+CSCs by GSI IX treatment. Notch1 impairment by GSI IX leads to inhibition of c-Myc 
(a direct downstream of Notch1). This in turn causes inactivation of both the pathways 
(Notch and wnt-beta-catenin) via inhibition of common downstreams. We also hypothesised 
that this crosstalk is on a whole mediated by CD44. Thus targeting of both Notch and wnt-
beta-catenin pathway active in CD44+CSCs, is effective for GSI IX treatment. 
 
Important cell regulatory downstream target genes like pAKT which plays a key role 
in multiple cellular processes such as glucose metabolism, apoptosis, cell 
proliferation, transcription and cell migration was altered (112). Additionally, Mitogen 
activated protein / extracellular signal-regulated kinase (MAP/ERK) pathway, and 
STAT3 (signal transducer and activator of transcription 3) associated with important 
role in control of cellular processes like proliferation, survival, differentiation and 
motility etc were effectively impaired (114, 115). Furthermore, RAC1 (Ras-related C3 
botulinum toxin substrate), a protein important for cell motility and cell growth is 
downregulated under GSI therapy (115). GSI treatment was able to impair important 
target genes, which all have leading functions or roles for cellular processes. As a 
new aspect, our data additionally showed GSI IX mediated effective inhibition of a 
cross talk between Notch and wnt-beta-catenin pathway via Notch1 in gastric CD44+ 
CSCs and indicated these two pathways as attractive targets for GSI mediated 
therapy. CD44 and specifically Notch1 silencing showed us an overall effective, 
similar downregulation of thecommon downstreams as achieved by GSI IX. Thus, 
these findings focusses on Notch1 in mediating the crosstalk and also highlights the 
importance of GSI IX treatment in gastric cancer . It also further strengthens that GSI 
targets CD44+ CSCs via inhibition of Notch1 which in turn helps in the concomitant 
inhibition of Notch / wnt-beta-catenin pathway. Our study revealed a new effective 
dual inhibitory approach for CSC mediated gastric cancer treatment.  
5.7 GSI IX impairs gastric CSC invivo via targeting CD44+ and Hes1+ double 
positive prognostic cells 
In accordance with our in vitro studiesin vivogrowth of CD44+ xenograft tumours was 
also inhibited under GSI IX treatment. Moreover, western blot analysis showed a 
consistant effective inhibition of the Notch wnt beta-catenincrosstalk after GSI IX 
treatment in these tumours. Importantly, FACS analysis using xenograft blood not 
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only revealed a strong connection between gastric cancer patients and xenografts 
reflecting the presence of double positive cells as a probable futuristic marker for 
gastric cancer prognosis but, additionally GSI IX treated xenografts showed an 
effective downregulation of these double positive (CD44+ and Hes1+) cells in 
comparison to the normal. Therefore, these results indicates GSI IX treatment as an 
effective therapeutic option to enhance the prognostic value and inhibit these double 
positive cells associated with gastric cancer development. Notably, the average 
count of double positive cells were maintained to the basal level under GSI IX 
treatment similar to that observed in normal individuals due to presence of CD44 
(CD44 is expressed in leucocytes and normal red blood cells)(117) and Hes1 (Notch 
and Hes1 expression is important for haematopoetic lineage in normal blood) (118) 
positive cells in normal blood. This indicates that GSI IX effectively inhibits the 
double positive gastric CSCs specifically without inhibiting the expression of these 
targets in normal individuals. 
5.8 GSI IX is a target specific drug against CD44+ CSCs 
To mitigate the off target toxic side effects of GSI IX treament and also to enforce the 
target specificity of GSI treatment reducing the chances of tumour relapse, we 
showed a comparitive analysis using proliferation assay of GSI IX treatment to that 
of 5Flurouracil (5FU). 5FU is a strong, standard chemotherapeutic regime used for 
gastric cancer treatment. 5FU treatment showed partial inhibition of both CD44+ and 
CD44- MKN45 cells proliferation whereas GSI IX treatment effectively inhibited and 
targeted CD44+ CSC population of MKN45 cells.Therefore, GSI IX treatment proved 
to be more effective and target /site specific in action as it particularly inhibits CD44+ 
CSCs in comparison to 5FU which fails to specifically inhibit CD44+ gastric CSCs 
and also exerts off target effects on CD44- population of gastric CSCs. GSI IX 
treatment therefore effectively removes all the boundaries associated with targeting 
CSC for cancer treatment and also hinders or blocks the chances of tumour relapse 
and resistancy of chemotherapies to gastric CSC. This is achieved by effective 
inhibition of both CSC associated pathway or feedback loop resulting in complete 
inhibition of gastric CSC mediated cancer progression. 
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5.9 Beneficial facts of our study 
Recently a study by Li et al.,2015 (119) also tested the inhibitory effect of GSI on 
CD44+ MKN45 cells both in vitro and in vivo similar to our present approach but their 
study differed in few aspects. The authorsdid not use more than one drug 
concentration of GSI and also lacked analysis of human data (119). Moreover, they 
showed considerable change of EMT markers like E-cadherin, N-cadherin, Vimentin 
etc in contrary to our study. Finally, Li and his colleagues in their study focused only 
on Notch1 signaling pathways unlike us as we check on both Notch and wnt-beta-
catenin pathway. However, using three different dosages of this drug our data 
showed an effective approach by achieving partial to complete inhibition in GSI IX 
therapy. We also highlighted the prognostic value of CD44+ and Hes1+ double 
positivity, importantly also revealed a strategy of GSI IX mediated inhibiton of Notch 
and wnt-beta-catenin pathway crosstalk involved in CD44 CSC exhibited gastric 
cancer progression. These additional findings prove our study to be of immense 
therapeutic interest with potential futuristic aspects for gastric cancer treatment 
specifically in the field of CSC in comparison to the previously published reports. 
5.10 Highlights and futuristic aspects of our study 
To summarise, for the first time our study shows the colocalisation of CD44 and 
Hes1 in CD44+ gastric CSC. We also highlight not only the colocalisation and 
activation of Notch signaling pathway (Hes1 is a direct downstream of Notch) in 
CD44+ CSCs, but also revealed the concomitant activation of wnt-beta-catenin 
pathway along with Notch in CD44+ gastric CSCs. Thus, we showed the importance 
of dual inhibition using single agent therapy GSI IX in these CD44+ gastric CSCs. 
Dual inhibition of both Notch and wnt-beta catenin pathway in CD44+ gastric CSC 
was achieved using GSI treatment which not only effectively inhibited both the 
pathways associated with CSC maintenance but also strongly blocked the chances 
of tumour relapse, which might occur due to the existence of feedback loop in 
between these two pathways in gastric cancer.  We also underlined the importance 
of CD44+ and Hes1+ as a prognostic marker in gastric cancer. CA19-9 is a widely 
accepted tumour marker for gastric cancer with prognostic importance(120). 
Therefore, for the first time we show the potential of CD44+and Hes1+ double 
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positive cells as a prognostic marker for gastric cancer. GSI IX mediated therapy can 
be specifically implemented to the group ofpatients showing CD44+ and Hes1+ 
double positivity as these cells also reflect the activation of the Notch pathway as a 
major contributor for CD44 maintenance.  So this proves anti Notch treatment like 
GSI IX as an effective option for this selective cohort of patients. Moreover, we also 
addressed GSI IX mediated effective inhibition of these double positive cells with 
prognostic value in CD44+ gastric CSC. The results from our study have significant 
implications for the treatment of gastric cancer. We also propose a probable 
mechanistic approach of GSI IX mediated treatment in gastric CSC but additional 
experiments are needed to determine our findings in a prospective study of gastric 
cancer patients.  Clinical trials using GSI IX as a probable therapeutic approach in 
gastric cancer patients could be of immense interest as it can open up new avenues 
for treatment of human gastric cancer .
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